Prospective, Randomized, Controlled, Multicenter, Pivotal, Clinical Investigation Evaluating the Safety and Efficacy of HEMOBLAST Bellows in Cardiothoracic, Abdominal, and Orthopedic Lower Extremity Surgeries
Phase: NA
Conditions: Hemostasis
Sponsor: Biom'Up France SAS

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 1 of 56 
 
 
 
 
PROSPECTIVE, RANDOMIZED, CONTROLLED, MULTICENTER, PIVOTAL, CLINICAL 
INVESTIGATION EVALUATING THE SAFETY AND EFFICACY OF HEMOBLASTTM 
BELLOWS IN CARDIOTHORACIC, ABDOMINAL, AND ORTHOPEDIC LOWER 
EXTREMITY SURGERIES 
 
CLINICAL INVESTIGATIONAL PLAN 
 
 
CIP Number 
ETC 2015-002 
CIP Version (Date) 
Version 4.0 (20 June 2016) 
 
Sponsor Address 
Biom’Up SA 
8, allée Irène Joliot Curie 
69800 Saint-Priest 
France 
 
US Representative of Company:  Elaine Whitmore, PhD 
 
Biom’Up Medical Expert:  William Spotnitz, MD 
                                            Chief Medical Officer, Biom’Up 
                                             
Sponsor Contacts 
Valérie Centis, Chief Scientific Officer 
Phone: +33 (0) 4 86 57 36 10 
Fax: +33 (0) 4 37 69 00 84 
E-mail: valerie.centis@biomup.com 
 
Elaine Whitmore, US Representative of Company 
Phone: +1 941 524 2546 
E-mail: ejwhitmore@verizon.net  
Monitor / Sponsor Representative 
NAMSA 
4050 Olson Memorial Hwy, Suite 450 
Minneapolis, MN 55422 
USA 
 
Phone: +1 (763) 287-3830 
            +1 (877) 814-7529 
 
Fax: +1 (763) 287-3836 
 
 
CONFIDENTIALITY STATEMENT: This is a confidential Biom’Up document.  Acceptance of this document 
constitutes the agreement by the recipient that no unpublished information contained herein will be published or 
disclosed without prior written approval from the Sponsor or Sponsor Representative.   
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 2 of 56 
 
Table of Contents 
 
1 
SYNOPSIS ............................................................................................................................................ 9 
2 
INTRODUCTION ............................................................................................................................... 11 
2.1 
Purpose ........................................................................................................................................ 11 
2.2 
Device Name ............................................................................................................................... 11 
2.3 
Intended Use ................................................................................................................................ 11 
2.4 
Study Overview ........................................................................................................................... 11 
2.4.1 
Duration of the Study .......................................................................................................... 11 
2.4.2 
Number of Subjects and Investigational Sites ..................................................................... 11 
2.5 
Sponsor Contact Information ...................................................................................................... 12 
3 
INVESTIGATIONAL DEVICE DESCRIPTION .............................................................................. 12 
3.1 
Investigational Device Description and Intended Use ................................................................ 12 
3.2 
Investigational Device Manufacturer Details .............................................................................. 12 
3.3 
Control Device ............................................................................................................................ 12 
3.4 
Device Storage and Accountability ............................................................................................. 14 
3.5 
Investigational Device Packaging and Labeling ......................................................................... 14 
4 
BACKGROUND AND RATIONALE ............................................................................................... 14 
4.1 
Definition of Hemostasis ............................................................................................................. 14 
4.2 
Current Hemostatic Therapeutic Strategies ................................................................................. 15 
4.3 
Assessment of Bleeding .............................................................................................................. 15 
4.4 
Rationale ...................................................................................................................................... 17 
5 
METHODOLOGY .............................................................................................................................. 18 
5.1 
Overall Study Design .................................................................................................................. 18 
5.1.1 
Objectives ............................................................................................................................ 18 
5.2 
Primary Efficacy Endpoint .......................................................................................................... 18 
5.3 
Secondary Efficacy Endpoints .................................................................................................... 18 
5.5          Subject Selection Criteria ......................................................................................................... 18 
5.5.1.3     Intraoperative Inclusion Criteria ......................................................................................... 20 
5.6        Point of Enrollment .................................................................................................................... 20 
5.7        Withdrawal Criteria .................................................................................................................... 20 
5.8 
Subject Compliance ..................................................................................................................... 21 
6 
INVESTIGATIONAL PROCEDURES .............................................................................................. 21 
6.1 
Schedule Overview ..................................................................................................................... 21 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 3 of 56 
 
6.2 
Screening Evaluations ................................................................................................................. 23 
6.2.1 
Informed Consent ................................................................................................................ 23 
6.2.2 
Preoperative Eligibility ....................................................................................................... 24 
6.2.3 
Subject Identification ........................................................................................................... 24 
6.3 
Preoperative Procedures and Evaluations ................................................................................... 24 
6.4 
Intraoperative Procedures and Evaluations ................................................................................. 25 
6.4.1 
Intraoperative Inclusion Criteria ......................................................................................... 25 
6.4.2 
Randomization and Hemostat Application ......................................................................... 25 
6.4.3 
Bleeding Severity and Hemostasis Evaluations .................................................................. 27 
6.4.4 
Other Bleeding Sites ............................................................................................................ 28 
6.4.5 
Intraoperative Data Collection ............................................................................................ 28 
6.5 
Postoperative Procedures and Evaluations .................................................................................. 29 
6.6 
Follow-Up Procedures and Evaluations ...................................................................................... 30 
6.7 
Discontinuation Procedures and Documentation ........................................................................ 30 
6.8 
Reoperation Documentation ........................................................................................................ 30 
7 
ADVERSE EVENTS .......................................................................................................................... 30 
7.1 
General ........................................................................................................................................ 30 
7.2 
Adverse Event Documentation .................................................................................................... 31 
7.3 
Reporting ..................................................................................................................................... 32 
7.4 
Regulatory Authority and Institutional Review Board Notifications .......................................... 33 
8 
INDEPENDENT DATA MONITORING COMMITTEE ................................................................. 33 
9 
DATA COLLECTION ........................................................................................................................ 34 
9.1 
Completion of Case Report Forms .............................................................................................. 34 
9.2 
Source Documentation ................................................................................................................ 34 
9.3 
Retention of Clinical Investigation Documentation .................................................................... 34 
9.4 
Training ....................................................................................................................................... 35 
10 
TERMINATION OF THE CLINICAL INVESTIGATION ........................................................... 35 
10.1 
Subject Withdrawals and Discontinuation .................................................................................. 35 
10.2 
Early Termination of the Clinical Investigation .......................................................................... 35 
11 
DATA MANAGEMENT ................................................................................................................ 36 
12 
STATISTICS ................................................................................................................................... 36 
12.1 
Overview ..................................................................................................................................... 36 
12.1.1 
Primary Efficacy Endpoint .................................................................................................. 36 
12.1.2 
Secondary Efficacy Endpoints ............................................................................................ 36 
12.1.3 
Safety Outcomes ................................................................................................................. 37 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 4 of 56 
 
12.1.4 
Individual Subject and Overall Study Success .................................................................... 37 
12.2 
General Analysis Considerations ................................................................................................ 37 
12.2.1 
Analysis Populations ........................................................................................................... 38 
12.2.2 
Handling of Missing Data ................................................................................................... 38 
12.2.3 
Subgroup Analyses .............................................................................................................. 38 
12.2.4 
Accounting for Multiple Comparisons ................................................................................ 38 
12.2.5 
Data Transformations .......................................................................................................... 39 
12.2.6 
Subject Disposition and Characteristics .............................................................................. 39 
12.2.7 
Subject Compliance ............................................................................................................. 39 
12.2.8 
Protocol Deviations ............................................................................................................. 39 
12.3 
Analytic Methods ........................................................................................................................ 40 
12.3.1 
Analysis of Primary and Secondary Efficacy Endpoints .................................................... 40 
12.3.2 
Analysis of Safety Outcomes .............................................................................................. 41 
12.4 
Interim Analyses ......................................................................................................................... 41 
12.4.1 
Interim Efficacy/Futility Analysis ....................................................................................... 41 
12.4.2 
Sample Size Justification .................................................................................................... 43 
12.4.3 
Implementation of the Stopping Boundary ......................................................................... 43 
13 
RISK/BENEFIT ANALYSIS ......................................................................................................... 44 
13.1 
Anticipated Clinical Benefits ...................................................................................................... 44 
13.2 
Risks Associated with Participation in the Clinical Investigation .............................................. 44 
13.3 
Risk/Benefit Analysis .................................................................................................................. 46 
13.4 
Conduct of Clinical Investigation to Reduce Risk ...................................................................... 46 
14 
REPORTS AND PUBLICATIONS ................................................................................................ 47 
14.1 
Interim Reports ............................................................................................................................ 47 
14.2 
Final Report ................................................................................................................................. 47 
14.3 
Publications ................................................................................................................................. 47 
15 
ETHICAL CONSIDERATIONS .................................................................................................... 47 
15.1 
Institutional Review Board Approval ......................................................................................... 47 
15.2 
Informed Consent and Patient Information ................................................................................. 47 
15.3 
Subject Confidentiality ................................................................................................................ 47 
15.4 
Declaration of Helsinki and IDE Regulations ............................................................................. 48 
15.5 
Indemnity .................................................................................................................................... 48 
15.6 
Insurance ..................................................................................................................................... 48 
16 
COMPLIANCE ............................................................................................................................... 48 
16.1 
Overview ..................................................................................................................................... 48 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 5 of 56 
 
16.2 
Clinical Investigation Personnel Responsibilities ....................................................................... 48 
16.3 
Monitoring ................................................................................................................................... 52 
16.4 
Audits .......................................................................................................................................... 52 
16.5 
Modifications to the Clinical Investigational Plan ...................................................................... 52 
17 
ABBREVIATIONS AND DEFINITIONS ..................................................................................... 53 
18 
REFERENCES ................................................................................................................................ 55 
 
Appendices 
Appendix A: HEMOBLAST™ Bellows Instructions for Use 
Appendix B: Sample Subject Informed Consent Form  
Appendix C: Sample Case Report Forms 
Appendix D: Investigator Training Plan 
Appendix E: Sample Investigator Agreement 
 
 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 6 of 56 
 
Clinical Investigational Plan 
 
Approval Page 
 
PROSPECTIVE, RANDOMIZED, CONTROLLED, MULTICENTER, PIVOTAL, CLINICAL 
INVESTIGATION EVALUATING THE SAFETY AND EFFICACY OF HEMOBLASTTM 
BELLOWS IN CARDIOTHORACIC, ABDOMINAL, AND ORTHOPEDIC LOWER 
EXTREMITY SURGERIES 
 
This Clinical Investigational Plan has been read and approved by: 
 
Sponsor 
Name 
Valérie Centis, PhD 
Title, Institution 
Chief Scientific Officer, Biom’Up 
Signature 
 
Date (DD/MMM/YYYY) 
 
 
Name 
William Spotnitz, MD 
Title, Institution 
Chief Medical Officer, Biom’Up 
Signature 
 
Date (DD/MMM/YYYY) 
20/JUNE/2016 
 
Sponsor Representative 
Name 
Rachel Hoffman 
Title, Institution 
Principal Medical Research Manager, NAMSA 
Signature 
Date (DD/MMM/YYYY) 
20/JUNE/2016 
 
Coordinating Investigator – United States 
Name 
William C Chapman, MD, FACS 
Title, Institution 
Professor of Surgery, Washington University in 
St. Louis 
Signature 
 
Date (DD/MMM/YYYY) 
 
 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 7 of 56 
 
Clinical Investigational Plan 
 
Principal Investigator Approval Page 
 
PROSPECTIVE, RANDOMIZED, CONTROLLED, MULTICENTER, PIVOTAL, CLINICAL 
INVESTIGATION EVALUATING THE SAFETY AND EFFICACY OF HEMOBLASTTM 
BELLOWS IN CARDIOTHORACIC, ABDOMINAL, AND ORTHOPEDIC LOWER 
EXTREMITY SURGERIES 
 
I, the undersigned, have read and understood the Clinical Investigational Plan specified above, and agree 
on the contents.  The Clinical Investigational Plan and the Clinical Investigation Agreement will serve as 
a basis for cooperation in the clinical investigation. 
 
Further, I agree to conduct the clinical investigation in accordance with the ethical principles that have 
their origin in the Declaration of Helsinki, guidelines of the International Conference on Harmonization 
(ICH) E6 Good Clinical Practice (GCP), United States (US) Code of Federal Regulations (CFR) [45 CFR 
Part 46; 21 CFR Parts 11, 50, 54, 56, and 812], and any other applicable national requirements. 
 
I am aware of my responsibilities as a Principal Investigator.  I agree to conduct the study according to 
these guidelines and to appropriately direct and assist the study staff. 
 
Principal Investigator Name 
 
Institution 
 
 
Principal Investigator Signature 
 
Date (DD/MMM/YYYY) 
 
 
 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 8 of 56 
 
Clinical Investigational Plan 
 
Revision History 
 
Version Number (Date) 
Summary of Revision(s) 
Justification for Revision(s) 
Version 1.0 (09 Feb 2015) 
None – new document  
Not applicable 
Version 2.0 (16 Mar 2016) 
• 
Remove spinal 
surgical arm 
• 
Change control 
device 
• 
Revise sample size 
and statistical 
section 
• 
Revise secondary 
efficacy endpoints 
• 
Revise 
inclusion/exclusion 
criteria 
• 
Take FDA recommendations 
into account 
• 
Select control that is widely 
used hemostat with similar 
components as investigational 
device 
• 
Statistical updates to be 
consistent with anticipated 
performance of control device 
• 
Add superiority as secondary 
efficacy endpoints 
• 
Ensure inclusion/exclusion 
criteria are consistent with 
previous communications with 
FDA and cardiothoracic 
surgical arm, and removal of a 
spinal surgical arm 
Version 3.0 (20 Apr 2016) 
• 
Addition of 
preoperative 
exclusion criterion 
regarding 
application of 
investigational or 
control device at site 
of synthetic graft or 
patch 
• 
Based on conference call with 
FDA on 20 April 2016 
Version 4.0 (20 June 2016) 
• 
Revise 
inclusion/exclusion 
criteria 
• 
Revise 
investigational 
device labeling 
information 
• 
Include antibody 
testing 
• 
Include additional 
details on control 
• 
Revise statistical 
section 
• 
Removal of 
Germany 
• 
Based on additional 
modifications for consideration 
in the FDA approval letter for 
G160063 dated April 22, 2016 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 9 of 56 
 
1 
SYNOPSIS 
 
Title 
Prospective, Randomized, Controlled, Multicenter, Pivotal, 
Clinical Investigation Evaluating the Safety and Efficacy of 
HEMOBLASTTM Bellows in Cardiothoracic, Abdominal, and 
Orthopedic Lower Extremity Surgeries  
Investigational Plan Number 
ETC 2015-002 
Purpose/Objectives 
To evaluate the safety and efficacy of a new hemostatic device 
(HEMOBLAST™ Bellows) compared to a control device, 
absorbable gelatin sponge USP with thrombin. 
Indication 
HEMOBLASTTM Bellows is intended for use in surgical 
procedures as an adjunct to hemostasis when control of bleeding 
by conventional procedures is ineffective or impractical, except in 
neurosurgical, ophthalmic, and urological procedures. 
Study Design 
Prospective, randomized, controlled 
Number of Subjects/Sites 
A maximum of 450 subjects enrolled across a maximum of 25 
investigational sites.  A maximum of 50 lead-in subjects will be 
enrolled, with 400 subjects randomized, enrolled, and included in 
the primary analysis for efficacy; all subjects will be evaluated for 
safety.   
Preoperative Inclusion Criteria 
A subject must meet all of the following preoperative inclusion 
criteria to be enrolled into the investigation: 
• 
Subject is undergoing an elective open cardiothoracic, 
abdominal, or orthopedic lower extremity surgery; 
• 
Subject or an authorized legal representative is willing and 
able to give prior written informed consent for 
investigation participation; 
• 
Subject undergoing cardiothoracic surgery is not allergic 
to protamine; and 
• 
Subject is 21 years of age or older. 
Preoperative Exclusion Criteria 
A subject must not meet any of the following preoperative 
exclusion criteria to be enrolled into the investigation: 
• 
Subject is undergoing a laparoscopic, thoracoscopic, or 
robotic surgical procedure; 
• 
Subject is undergoing a neurologic surgical procedure; 
• 
Subject is undergoing a spinal surgical procedure; 
• 
Subject is undergoing an emergency surgical procedure; 
• 
Subject is pregnant, planning on becoming pregnant 
during the follow-up period, or actively breast-feeding; 
• 
Subject has a clinically significant coagulation disorder or 
disease, defined as a platelet count < 100,000 per 
microliter or International Normalized Ratio > 1.5 within 
4 weeks of surgery; 
• 
Subject receiving intravenous heparin within 12 hours 
before surgery or oral Coumadin within 2 days before 
surgery; 
• 
Subject receiving antiplatelet medications within 5 days 
prior to surgery;  
• 
Subject undergoing abdominal or orthopedic lower 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 10 of 56 
 
extremity surgery receiving aspirin within 7 days prior to 
surgery; 
• 
Subject has an active or suspected infection at the surgical 
site; 
• 
Subject has had or has planned to receive any organ 
transplantation; 
• 
Subject has a known sensitivity or allergy to bovine and/or 
porcine substance(s) or any other component(s) of the 
hemostatic agent; 
• 
Subject has ASA classification of 5; 
• 
Subject has a life expectancy of less than 3 months; 
• 
Subject has a known psychiatric disorder, which in the 
opinion of the Principal Investigator, would preclude the 
subject from completing this clinical study; 
• 
Subject has a documented severe congenital or acquired 
immunodeficiency; 
• 
Subject has religious or other objections to porcine, 
bovine, or human components;  
• 
Subject in whom the investigational or control device will 
be used at the site of a valve replacement or repair; 
• 
Subject in whom the investigational or control device will 
be used at the site of a synthetic graft or patch implant; 
• 
Subject is currently participating or has participated in 
another clinical trial within the past 30 days and is 
receiving/has received an investigational drug, device, or 
biologic agent; and 
• 
Subject is not appropriate for inclusion in the clinical trial, 
per the medical opinion of the Principal Investigator. 
Intraoperative Inclusion 
Criteria 
A subject must meet all of the following intraoperative inclusion 
criteria to be enrolled into the investigation: 
• 
Subject does not have an active or suspected infection at 
the surgical site; 
• 
Subject undergoing cardiothoracic surgery with 
anticoagulation must have anticoagulation reversed prior 
to target bleeding site (TBS) identification and treatment; 
• 
Subject in whom the Investigator is able to identify a TBS 
for which any applicable conventional means for 
hemostasis are ineffective or impractical; and 
• 
Subject has a TBS with an SBSS score of 1, 2, or 3. 
Length of Investigation 
The estimated duration of the study is approximately 10 months 
from the time of first subject enrollment to the last study protocol-
required follow-up visit.   
Follow-Up Schedule 
6 ± 2 weeks postoperatively 
Investigational Device 
HEMOBLAST™ Bellows (Biom’Up, France), hereinafter referred 
to as HEMOBLAST™ 
Comparator Device 
Surgifoam® (Ethicon™; Somerville, New Jersey) with 
Recothrom® (Zymogenetics, Inc.; Seattle, Washington); 
absorbable gelatin sponge USP and thrombin, hereinafter referred 
to as G+T 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 11 of 56 
 
Primary Endpoint 
The primary efficacy endpoint of this clinical investigation is non-
inferiority of HEMOBLAST™ relative to G+T for success at 
achieving hemostasis within 6 minutes. 
Secondary Endpoints 
The secondary efficacy endpoints of this clinical investigation are: 
• 
Superiority of HEMOBLAST™ relative to G+T in mean 
preparation time from the opening of package to product 
being ready to use; 
• 
Non-inferiority of HEMOBLAST™ relative to G+T for 
success at achieving hemostasis within 3 minutes;  
• 
Superiority of HEMOBLAST™ relative to G+T for 
success at achieving hemostasis within 6 minutes; and 
• 
Superiority of HEMOBLAST™ relative to G+T for 
success at achieving hemostasis within 3 minutes. 
 
2 
INTRODUCTION 
 
2.1 
Purpose 
 
The purpose of this study is to evaluate the safety and efficacy of HEMOBLAST™ Bellows, a hemostatic 
device. 
 
2.2 
Device Name 
 
HEMOBLAST™ Bellows (hereinafter referred to as HEMOBLAST™) will be used in this study. 
 
2.3 
Intended Use 
 
HEMOBLAST™ is intended for use in surgical procedures as an adjunct to hemostasis when control of 
bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, ophthalmic, 
and urological procedures. 
 
2.4 
Study Overview 
 
2.4.1 
Duration of the Study 
 
The estimated duration of the study is approximately 10 months from the time of first subject enrollment 
to the last study protocol-required follow-up visit.  Each subject will be followed for 6 ± 2 weeks. 
 
2.4.2 
Number of Subjects and Investigational Sites 
 
A maximum of 450 subjects will be enrolled across a maximum of 25 investigational sites in the United 
States.  Four hundred patients will be randomized, enrolled, and evaluated for efficacy (Time to 
Hemostasis [TTH] Population).  There will be a maximum of 50 lead-in subjects (one per enrolling 
investigator). 
 
On average, approximately 18 subjects will be enrolled per site, with no more than 15% of the total TTH 
Population (60 subjects) being enrolled at any single site.   
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 12 of 56 
 
2.5 
Sponsor Contact Information 
 
Biom’Up SA 
8, allée Irène Joliot Curie 
69800 Saint-Priest 
France 
 
Valérie Centis, Chief Scientific Officer 
Phone: +33 (0) 4 86 57 36 10 
Fax: +33 (0) 4 37 69 00 84 
 
Elaine Whitmore, US Representative of Company 
Phone: +1 941 524 2546 
E-mail: ejwhitmore@verizon.net 
 
3 
INVESTIGATIONAL DEVICE DESCRIPTION 
 
3.1 
Investigational Device Description and Intended Use 
 
The HEMOBLAST™ consists of collagen, chondroitin sulfate, and thrombin powder. The powder is dry, 
sterilized, biocompatible, and non-pyrogenic. It is resorbed within 4 weeks. No preparation, mixing, or 
heating is required.  
 
HEMOBLAST™ is composed predominantly of highly purified porcine collagen with smaller amounts of 
bovine chondroitin sulfate and human derived thrombin. Each device contains a maximum of 1500 IU of 
thrombin in 1.65 g of powder. Plasma donations are from US plasma centers only. All individual 
donations of the plasma were tested for HBsAg, anti-HIV1/-HIV2, and anti-HCV and found to be 
negative. The plasma pools were tested and found to be non-reactive for HCV RNA, HBV DNA, and 
HIV1 RNA as determined by PCR (NAT). The product complies with the specifications of the 
manufacturer and WHO.  
 
The manufacturing procedures for HEMOBLAST™ include processing steps designed to reduce the risk 
of viral transmission. 
 
HEMOBLAST™ Bellows is intended for use in surgical procedures as an adjunct to hemostasis when 
control of bleeding by conventional procedures is ineffective or impractical, except in neurosurgical, 
ophthalmic, and urological procedures.  
 
The Instructions for Use are included as Appendix A. 
 
3.2 
Investigational Device Manufacturer Details 
 
The manufacturer of the HEMOBLAST™ investigational device is Biom’Up, which is located in Saint 
Priest, France.  Biom’Up is ISO 13485 certified. 
 
3.3 
Control Device 
 
The control device for this clinical investigation is absorbable gelatin sponge USP with thrombin 
(hereinafter referred to as G+T).  Specifically, the absorbable gelatin sponge USP will be Surgifoam® 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 13 of 56 
 
(Ethicon™; Somerville, New Jersey).  The thrombin will be Recothrom® 5mL kit (Zymogenetics, Inc.; 
Seattle, Washington). 
Recothrom® labeling also states “RECOTHROM may be used in conjunction with an absorbable gelatin 
sponge, USP.”  
G+T was selected as the control because: 
1. G+T is one of the most frequently used hemostats in the US;1 
2. G+T components are similar to those in HEMOBLAST™; 
a. Surgifoam® is composed of porcine gelatin, 
b. Recothrom® is topical recombinant human thrombin and contains 5,000 IU of thrombin 
in the 5mL kit  with a concentration of 1,000 IU/mL of thrombin, 
c. The risk profile of G+T is similar to that of HEMOBLAST™, due to the similarity of 
components and type of thrombin (recombinant human thrombin). 
3. 
FDA has recognized G+T as an appropriate control in other hemostatic agent studies, as 
summarized in Table 1 below.  These studies include use in all three of the surgical applications 
that will be included in this pivotal clinical investigation (cardiothoracic, abdominal, and 
orthopedic).  The use of G+T has been approved for each of these types of surgery and its safety 
and efficacy is supported with clinical data.1, 2, 3, 4, 5 
 
Table 1.  Hemostatic Product Clinical Trials 
Biologic 
Hemostatic 
Product 
Surgical Arms 
Control 
Hemostat 
Source 
Raplixa 
Cardiovascular, 
Spine, General 
(liver, soft tissue) 
Gelatin sponge 
U.S. Food and Drug Administration, Center for Biologics 
Evaluation and Research. FDA approves Raplixa to help control 
bleeding during surgery; FDA News Release, April 30, 2015. 
http://www.fda.gov/newsevents/newsroom/pressannouncements/u
cm445247.htm  
 
U.S. Food and Drug Administration, Center for Biologics 
Evaluation and Research. Summary Basis for Regulatory Action: 
Raplixa Fibrin Sealant, April 3, 2015. 
http://www.fda.gov/downloads/BiologicsBloodVaccines/BloodBl
oodProducts/ApprovedProducts/LicensedProductsBLAs/Fractiona
tedPlasmaProducts/UCM447129.pdf 
Recothrom 
Cardiovascular, 
Spine, Abdominal 
Bovine thrombin 
+ Gelfoam 
U.S. Food and Drug Administration, Center for Biologics 
Evaluation and Research. Chairman’s Summary—RECOTHROM, 
January 11, 2008. 
http://www.fda.gov/BiologicsBloodVaccines/BloodBloodProducts
/ApprovedProducts/LicensedProductsBLAs/FractionatedPlasmaPr
oducts/ucm120565.htm 
Medical Device 
Floseal 
Cardiac, Vascular, 
Spine 
Gelfoam + 
Thrombin 
U.S. Food and Drug Administration, Center for Devices and 
Radiological Health. Summary of Safety and Effectiveness; 
FloSeal™ Matrix P990009, December 8, 1999. 
http://www.accessdata.fda.gov/cdrh_docs/pdf/P990009b.pdf 
Surgifoam 
Cardiovascular, 
Orthopedic, 
Gelfoam 
U.S. Food and Drug Administration, Center for Devices and 
Radiological Health. Summary of Safety and Effectiveness; 
Surgifoam Absorbable Gelatin Sponge USP, P990004, September 
                                                            
1 DNA Ink Study.  US hemostat sales. (IMS MIDAS 2013, Evaluate Pharma 2013, Frost & Sullivan 2006 & 2008); 
market research report retained at Sponsor 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 14 of 56 
 
General 
30, 1999. 
http://www.accessdata.fda.gov/cdrh_docs/pdf/P990004b.pdf  
 
 
3.4 
Device Storage and Accountability 
 
Following the execution of all applicable contracts, receipt of essential documents from the 
investigational site, and approval by the applicable Regulatory Authorities (FDA) and applicable 
Institutional Review Boards (IRBs), investigational product will be shipped to the investigational site.  
The Sponsor is responsible for the traceability and accountability for the investigational product being 
used in this study. 
 
Investigational product will be traced using lot numbers.  The Sponsor or designated Sponsor 
representative will verify that the investigational device is being properly stored and accounted for during 
the conduct of the clinical investigation.  Each investigational site will identify a designee who will be 
held responsible for controlling the investigational device and ensuring that it is dispensed only for the 
purposes of this investigation.  This designee will be expected to retain all unopened, unused, 
investigational product supplied until the completion of the investigation or until the Sponsor or 
designated Sponsor representative has made arrangements for the return or proper destruction of unused 
investigational product. 
 
3.5 
Investigational Device Packaging and Labeling 
 
HEMOBLAST™, the investigational device, is supplied as bellows pre-loaded with hemostatic powder.  
The bellows contains 1.65g of implant material.  The product is sterilized using gamma irradiation and is 
provided in double-packaging. 
 
HEMOBLAST™ will be specifically labeled for this investigation as “Investigational Product” per 
applicable laws and regulations.  Use of the device outside of this clinical investigational plan is strictly 
prohibited; further, the instructions for use will be strictly followed. 
 
4 
BACKGROUND AND RATIONALE 
 
4.1 
Definition of Hemostasis 
  
Despite advances in surgical techniques, excessive bleeding remains a major complication associated with 
surgery and contributes to poor clinical outcomes.6  There is no universally accepted definition of 
hemostasis.  The most current definition is the “cessation of bleeding.”7  The term comes from the Greek 
roots heme (blood) and stasis (halt).  Hemostasis can be considered as control of bleeding within the 
finely tuned balance of procoagulant, anticoagulant, fibrinolytic, and anti-fibrinolytic activities.8 
 
Hemostasis refers to the process of causing blood to form a clot (the opposite of hemostasis is 
hemorrhage).  Most of the time, this process includes the changing of blood from a fluid to a solid state.  
Intact blood vessels are central to moderating blood’s tendency to clot.  The endothelial cells of intact 
vessels prevent blood coagulation by secretion of heparin-like molecules and thrombomodulin and 
prevent platelet aggregation by the secretion of nitric oxide and prostacyclin.  When endothelial injury 
occurs, the endothelial cells cease secretion of coagulation and aggregation inhibitors and instead secret 
von Willebrand factor and tissue thromboplastin which initiate the maintenance of hemostasis after injury.  
Hemostasis has three major steps: vasoconstriction, formation of a platelet plug, and blood coagulation. 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 15 of 56 
 
4.2 
Current Hemostatic Therapeutic Strategies 
 
Hemorrhage control is vital for successful clinical outcomes after surgery.  It is essential to decrease 
postoperative morbidity and operative time, leading to potential cost savings.9, 10, 11 During surgical 
operations, it is important to maintain a fine balance between bleeding and clotting so that blood 
continues to flow to the tissues at the surgical site without excessive blood loss.  There are many tools 
used for hemorrhage control; these include preventive measures, transfusion of blood products, and 
traditional methods.6 
 
A variety of manual, mechanical, and thermal techniques are available for maintaining hemostasis in 
surgery.  Application of direct pressure or compression at a bleeding site is often the Investigator’s first 
choice to assist in the control of bleeding.  The placement of direct pressure over the injury site serves to 
compress vascular structures and promote localized clotting.  Direct pressure, while widely accepted as 
standard of care for the control of all levels of bleeding severity, has limited discourse in the surgical 
literature.  Other mechanical methods, including sutures, staples, and ligating clips, are useful if the 
source of bleeding is easily identifiable and able to be sealed.11 
 
Compression and other mechanical methods may not be appropriate during all surgical procedures; this 
method of controlling bleeding may not be sufficient when the source of bleeding is hard to identify, as 
for diffuse venous bleeding.12  Moreover, the mechanical methods are not applicable in some surgical 
procedures because of localization and the inaccessibility of structures.  
 
To summarize, these techniques show their limits in terms of bleeding control efficacy.11, 12, 13, 14, 15 
Furthermore, they may be associated with the occurrence of complications.14 
 
Since ancient times, hemostasis has also been facilitated by application of local agents.16  One of the 
earliest local hemostatic agents was cotton, in the form of gauze sponges.  Absorbable local hemostatic 
agents have since been developed and they currently provide useful adjunctive therapy when conventional 
methods of hemostasis are ineffective or impractical.  Local agents can be applied directly to the bleeding 
site and may prevent continuous bleeding throughout the entire surgical procedure and during the post-
operative recovery period. 
 
4.3 
Assessment of Bleeding 
 
A method for the consistent assessment of bleeding that is applicable to any surgical procedure is 
important for use in a clinical investigation assessing the performance of a hemostatic agent. 
 
The goal is to ensure that the hemostat is applied when control of bleeding by conventional procedures is 
ineffective or impractical, but not applied to severe bleeding for which hemostatic agent is not designed to 
control.  It is also important to ensure consistency of bleeding severity assessments across investigators 
and that similar bleeding severities are enrolled during the trial. 
 
An estimate of total intraoperative blood loss is an integral part of any surgical procedure and is 
considered routine care.  The wide variety of surgical specialties and operations make quantitative 
standardization of total blood loss difficult, yet estimates may still be provided.  Estimating total blood 
loss during a surgical procedure, supplemented with other variables such as blood pressure, are data 
helpful for the ongoing evaluation of a subject’s condition and the assessment/modification of intra- and 
post-operative management. 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 16 of 56 
 
A tool to assess the severity of intraoperative bleeding at a target bleeding site (TBS) has been developed 
and validated by the Sponsor.  This Surface Bleeding Severity Scale (SBSS) will be used to evaluate 
bleeding, as well as hemostasis, for the purposes of this clinical investigation. 
 
The SBSS was developed by Biom’Up in cooperation with the FDA.  This method of bleeding severity 
assessment was validated in preclinical and clinical studies and will be used in this clinical investigation.  
The utility of the SBSS was confirmed in a clinical setting during the pilot clinical investigation, also 
providing initial data on the safety and efficacy of HEMOBLAST™.  The agreement between 
Investigators utilizing the SBSS in the pilot clinical study met all pre-defined criteria.  Satisfactory 
assessment with respect to agreement of bleeding severity, hemostasis, and eligibility using the SBSS was 
demonstrated in the pilot clinical investigation, substantiating its use in this pivotal clinical investigation. 
 
Severity of bleeding of the TBS for each subject in the clinical investigation will be assessed by 
assignment of an SBSS score, as defined in Table 2 below. 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 17 of 56 
 
Table 2.  Surface Bleeding Severity Scale (SBSS) 
SBSS Score 
0 
1 
2 
3 
4 
5 
Verbal Descriptor 
None 
Minimal 
Mild 
Moderate 
Severe; not 
immediately 
life-
threatening 
Extreme; 
immediately 
life-
threatening 
Visual Descriptor 
Dry 
Oozing 
Pooling 
Flowing 
Streaming 
Gushing 
Expected 
Intervention(s) 
None 
Manual 
pressure, 
cautery, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
staples, 
tissue repair 
Manual 
pressure, 
cautery, 
suture, 
staples, 
tissue repair 
Maximum 
Expected ACS-
ATLS2 Shock Risk 
Class 
1 
1 
1 
2 
3 
4 
1 ACS-ATLS Shock Risk Class: 1 – involves up to 15% of blood volume; typically no change in vital signs and fluid 
resuscitation is not usually necessary.  Class 2 – involves 15-30% of total blood volume; patient is often tachycardic 
with a narrowing of the difference between the systolic and diastolic blood pressures; the body attempts to 
compensate with peripheral vasoconstriction; skin may start to look pale and be cool to the touch; volume 
resuscitation with crystalloids is all that is typically required; blood transfusion is not typically required.  Class 3 – 
involves loss of 30-40% of circulating blood volume; patient’s blood pressure drops; heart rate increases, peripheral 
hypoperfusion worsens; fluid resuscitation with crystalloid and blood transfusion are usually necessary.  Class 4 – 
involves loss of > 40% of circulating blood volume; the limit of the body’s compensation is reached and aggressive 
resuscitation is required to prevent death. 
 
The SBSS will be used to determine the intraoperative eligibility (described further in Section 5.5.1.3) as 
well as hemostatic success (described further in Section 6.4.3).  Use of the SBSS will ensure consistent 
enrollment of TBSs of similar bleeding severities and help ensure subject safety by excluding those who 
have severe bleeding. 
 
Investigators will be trained and tested on the SBSS prior to their enrollment of any subjects into the 
clinical investigation, as described further in Appendix D. 
 
4.4 
Rationale 
 
Although the properties of the ideal local hemostatic agent may vary according to the surgical specialty, 
some properties are universally valued including: rapid and effective control/cessation of bleeding; ability 
to make effective contact with the bleeding surface; acceptable safety profile; and ease of preparation and 
use. 
 
According to Spotnitz et al, the ideal hemostat, sealant or adhesive must have certain performance 
characteristics (safety, efficacy, usability, cost, and approvability) that enable it to be used by 
Investigators.17  No single product can yet be used for all potential applications.  The challenge is to 
develop a local agent that may combine all those characteristics. 
 
Biom’Up (France) has developed and manufactured a new medical device, HEMOBLAST™, which is 
intended for use in surgical procedures as an adjunct to hemostasis when control of bleeding by 
                                                            
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 18 of 56 
 
conventional procedures is ineffective or impractical.  A clinical investigation is warranted to assess the 
safety and efficacy of this hemostat. 
 
5 
METHODOLOGY 
 
5.1 
Overall Study Design 
 
This is a prospective, randomized, controlled, multicenter, clinical investigation. 
 
5.1.1 
Objectives 
 
The objective of this pivotal clinical investigation is to evaluate the safety and efficacy of a new 
hemostatic device (HEMOBLAST™) compared to G+T. 
 
5.2 
Primary Efficacy Endpoint 
 
The primary efficacy endpoint of this clinical investigation is non-inferiority of HEMOBLAST™ relative 
to G+T for success at achieving hemostasis within 6 minutes. 
 
5.3 
Secondary Efficacy Endpoints 
 
The secondary efficacy endpoints of this clinical investigation are: 
 
• 
Superiority of HEMOBLAST™ relative to G+T in mean preparation time from the opening of 
package to product being ready to use; 
• 
Non-inferiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 3 
minutes;  
• 
Superiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 6 
minutes; and 
• 
Superiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 3 
minutes. 
 
5.4    Additional Exploratory Outcomes 
   
The additional exploratory outcomes of this clinical investigation that will be described and quantified 
are: 
 
• 
Operative time for HEMOBLAST™ subjects compared to G+T subjects; 
• 
Duration of hospitalization for HEMOBLAST™ subjects compared to G+T subjects; and 
• 
Number of units of blood transfused intraoperatively for HEMOBLAST™ subjects compared to 
G+T subjects. 
 
5.5          Subject Selection Criteria 
 
A maximum of 450 (400 efficacy, maximum of 50 lead-in) subjects undergoing elective open 
cardiothoracic, abdominal, and orthopedic lower extremity surgeries will be enrolled into the clinical 
investigation.  Subjects will need to meet all eligibility criteria to be enrolled into the investigation, as 
detailed below. 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 19 of 56 
 
5.5.1.1     Preoperative Inclusion Criteria 
 
A subject must meet all of the following preoperative inclusion criteria to be enrolled into the 
investigation: 
 
• 
Subject is undergoing an elective open cardiothoracic, abdominal, or orthopedic lower extremity 
surgery; 
• 
Subject or an authorized legal representative is willing and able to give prior written informed 
consents for investigation participation; 
• 
Subject undergoing cardiothoracic surgery is not allergic to protamine; and 
• 
Subject is 21 years of age or older. 
 
5.5.1.2      Preoperative Exclusion Criteria 
 
A subject must not meet any of the following preoperative exclusion criteria to be enrolled into the 
investigation: 
 
• 
Subject is undergoing a laparoscopic, thoracoscopic or robotic surgical procedure; 
• 
Subject is undergoing a neurologic surgical procedure; 
• 
Subject is undergoing a spinal surgical procedure; 
• 
Subject is undergoing an emergency surgical procedure; 
• 
Subject is pregnant, planning on becoming pregnant during the follow-up period, or actively 
breast-feeding; 
• 
Subject has a clinically significant coagulation disorder or disease, defined as a platelet count < 
100,000 per microliter or International Normalized Ratio > 1.5 within 4 weeks of surgery; 
• 
Subject receiving intravenous heparin within 12 hours before surgery or oral Coumadin within 2 
days before surgery; 
• 
Subject receiving antiplatelet medications within 5 days prior to surgery;  
• 
Subject undergoing abdominal or orthopedic lower extremity surgery receiving aspirin within 7 
days prior to surgery; 
• 
Subject has an active or suspected infection at the surgical site; 
• 
Subject has had or has planned to receive any organ transplantation; 
• 
Subject has a known sensitivity or allergy to bovine and/or porcine substance(s) or any other 
component(s) of the hemostatic agent; 
• 
Subject has ASA classification of 53; 
• 
Subject has a life expectancy of less than 3 months; 
• 
Subject has a known psychiatric disorder, which in the opinion of the Principal Investigator, 
would preclude the subject from completing this clinical study; 
• 
Subject has a documented severe congenital or acquired immunodeficiency; 
• 
Subject has religious or other objections to porcine, bovine, or human components;  
• 
Subject in whom the investigational or control device will be used at the site of a valve 
replacement or repair; 
• 
Subject in whom the investigational or control device will be used at the site of a synthetic graft 
or patch implant; 
                                                            
3 ASA Classification: 1 – normal health patient; 2 – patient with mild systemic disease; 3 – patient with severe 
systemic disease; 4 – patient with severe systemic disease that is constant threat to life; 5 – moribund patient who is 
not expected to survive with the operation; 6 – a declared brain-dead patient whose organs are being removed for 
donor purposes 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 20 of 56 
 
• 
Subject is currently participating or has participated in another clinical trial within the past 30 
days and is receiving/has received an investigational drug, device, or biologic agent; and 
• 
Subject is not appropriate for inclusion in the clinical trial, per the medical opinion of the 
Principal Investigator. 
 
5.5.1.3     Intraoperative Inclusion Criteria 
 
A subject must meet all of the following intraoperative inclusion criteria to be enrolled into the 
investigation: 
 
• 
Subject does not have an active or suspected infection at the surgical site; 
• 
Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation 
reversed prior to Target Bleeding Site (TBS) identification and treatment; 
• 
Subject in whom the Investigator is able to identify a TBS for which any applicable conventional 
means for hemostasis are ineffective or impractical; and 
• 
Subject has a TBS with an SBSS score of 1, 2, or 3. 
 
Table 3.  Enrollment Based on SBSS Score 
SBSS Score 
0 
1 
2 
3 
4 
5 
Verbal 
Descriptor 
None 
Minimal 
Mild 
Moderate 
Severe; not 
immediately 
life-
threatening 
Extreme; 
immediately 
life-
threatening 
Visual 
Descriptor 
Dry 
Oozing 
Pooling 
Flowing 
Streaming 
Gushing 
Expected 
Intervention(s) 
None 
Manual 
pressure, 
cautery, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
staples, tissue 
repair 
Manual 
pressure, 
cautery, 
suture, 
staples, tissue 
repair 
Maximum 
Expected 
ACS-ATLS 
Shock Risk 
Class 
1 
1 
1 
2 
3 
4 
Eligible for 
Enrollment 
No 
Yes 
Yes 
Yes 
No 
No 
 
 
5.6        Point of Enrollment 
 
All patients presenting to the Investigator for elective (non-emergent) open cardiothoracic, abdominal, or 
orthopedic lower extremity surgical procedures are potential study subjects and should be screened for 
eligibility.  Subjects will need to meet all eligibility in order to be enrolled into the investigation. 
 
A subject is enrolled when he/she meets all preoperative inclusion/exclusion criteria, signs the informed 
consent forms, and meets the intraoperative inclusion criteria.  The point of enrollment into the clinical 
investigation will occur intraoperatively.   
 
5.7        Withdrawal Criteria 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 21 of 56 
 
 
Subjects may withdraw from the clinical investigation at any time without providing a reason.  Subjects 
will not be penalized nor lose any benefits to which they are otherwise entitled if they should choose to 
withdraw.  The Investigator may also choose to withdraw the subject if he or she feels that this is in the 
subject’s best interest. 
 
The possible situations for subject withdrawal will be managed as such:  
 
• 
Subjects who withdraw from the study after receiving investigational device will be followed for 
safety through the end of the study if they agree.  Efforts will be made to collect any final data 
and information regarding the reason for withdrawal.  Data collected prior to withdrawal from the 
study may be used in in study analyses; or 
• 
Subjects who withdraw from the study before receiving investigational device receive routine 
care.  No study-specific safety or efficacy assessments will be conducted. 
 
5.8 
Subject Compliance 
 
Every reasonable effort will be made to maintain subject compliance and participation in the clinical 
investigation until final follow-up is completed.   
 
Subject loss to follow-up is not expected to impact the efficacy analysis, as the efficacy endpoints are 
collected intraoperatively.  However, it is still important for subjects to complete the 6 ± 2 week follow-
up to assess safety.  The investigational site will make all reasonable efforts to contact those subjects who 
do not return for the 6 ± 2 week follow-up visit to collect as much follow-up information as possible to 
assess investigational device safety. 
 
6 
INVESTIGATIONAL PROCEDURES 
 
6.1 
Schedule Overview 
 
Table 3 details the clinical investigation visits, corresponding timing, and evaluations to be performed at 
the visit.  Table 4 lists the CRFs that need to be completed at each visit.  Figure 1 represents the subjects’ 
participation in the clinical investigation. 
 
Table 4.  Investigational Evaluation Schedule 
Visit 
Timing 
Evaluations 
Preoperative 
Within 4 weeks before surgery 
Informed consent, preoperative eligibility criteria 
confirmation, preoperative evaluations, and blood 
draw for antibody evaluation 
Intraoperative 
Day of surgery; day 0 
Intraoperative inclusion criteria confirmation, 
efficacy assessments, and safety assessments 
Postoperative 
Postoperative day 1 
Safety assessments 
6 Week Follow-Up 
6 weeks (± 2 weeks) 
postoperatively 
Safety assessments, blood draw for antibody 
evaluation, and study discontinuation 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 22 of 56 
 
Table 5.  CRF Completion Schedule 
CRF 
Screening 
Preoperative 
Intraoperative 
Postoperative 
Follow-Up 
Discontinuation 
Preoperative Eligibility CRF 
X 
 
 
 
 
 
Preoperative CRF 
 
X 
 
 
 
 
Intraoperative CRF 
 
 
X 
 
 
 
Concomitant Medication CRF 
 
O 
O 
O 
O 
 
Laboratory CRF 
 
X 
 
X 
 
 
Postoperative CRF 
 
 
 
X 
 
 
Follow-Up CRF 
 
 
 
 
X 
 
Discontinuation CRF 
 
 
 
 
 
X 
Adverse Event CRF 
 
 
O 
O 
O 
 
Device Deficiency CRF 
 
 
O 
 
 
 
Reoperation CRF 
 
 
 
O 
O 
 
 
X 
Mandatory 
O 
As applicable 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 23 of 56 
 
Figure 1.  Subject Participation in the Clinical Investigation 
 
 
 
6.2 
Screening Evaluations 
 
6.2.1 
Informed Consent 
 
Prior to performing any study specific procedures, a detailed explanation of the study procedures, 
potential discomforts, risks and benefits of participation, and alternatives will be reviewed with 
potential study subjects by a qualified member of the study team.  The informed consent process 
will follow applicable institutional and regulatory guidelines.  Subjects will be provided adequate 
Subject screened and written 
Informed Consent obtained 
Subject meets preoperative 
inclusion / exclusion criteria 
Preoperative procedures and 
evaluations 
Meets intraoperative inclusion 
criteria 
RANDOMIZED & ENROLLED 
Intraoperative procedures and 
evaluations 
Postoperative procedures and 
evaluations 
6 week follow-up assessments 
DISCONTINUATION 
YES 
YES 
NO 
NOT ENROLLED 
NO 
HEMOBLAST™ 
application 
G+T  
application 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 24 of 56 
 
time to review the informed consent document and all questions will be answered to the 
satisfaction of the subject prior to signing the informed consent.   
If the subject is willing to participate in the clinical investigation, he/she or an authorized legal 
representative must sign the informed consent form indicating that they have read and understand 
the information provided.  Each site will follow their local IRB and applicable regulatory 
guidelines for obtaining informed consent.  Documentation of the informed consent process for 
each subject and the original signed informed consent will be retained at the site and as required 
by applicable regulations. 
6.2.2 
Preoperative Eligibility 
 
Once written informed consent has been obtained, the Preoperative Eligibility CRF will be 
completed to document adherence to the preoperative inclusion and exclusion criteria from 
Section 5.5. 
 
Where a subject fails to fulfill any element of the preoperative eligibility criteria, this will be 
documented and any signed consent form and completed preoperative inclusion/exclusion criteria 
retained by the Principal Investigator.  The subject will not be advanced any further into this 
clinical investigation. 
 
6.2.3 
Subject Identification 
 
After a subject has signed informed consent and/or met the preoperative inclusion and exclusion 
criteria, the subject will be allocated to the next available investigation number (subject ID 
number). 
 
The subject ID number will consist of the site number and the subject number.  The subject 
number will be 01 for the first subject, 02 for the second subject and so on.  This subject ID 
number will be the unique identifier of the subject and included on each CRF page and all other 
investigational documentation relating to that subject. 
 
6.3 
Preoperative Procedures and Evaluations 
 
The following data will be collected and recorded at the preoperative visit on the Preoperative CRF: 
 
• 
Demographic data; 
o Age, 
o Gender, 
o Race and ethnicity, 
• 
Physical exam and laboratory tests;  
o Height, 
o Weight, 
o Diastolic and systolic blood pressure, 
o CBC (Laboratory CRF), 
o Coagulation status (Laboratory CRF), 
o Chemistry panel (Laboratory CRF), 
o Pregnancy test for females of child-bearing age (Laboratory CRF), 
o Blood draw for antibody testing, 
• 
Medical history; and 
o Coagulation disorder(s), 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 25 of 56 
 
o History of bleeding requiring hospitalization in the last five years, 
o Disease process / indication for surgery, 
o Concomitant illnesses, 
o Surgical history related to the surgical area, 
o Diabetes, 
o Smoking history, 
o Malignancies and prior therapies, 
o Hepatic disease, 
o Concomitant medications potentially impacting coagulation status (Concomitant 
Medication CRF). 
 
The Laboratory CRF will be completed and applicable concomitant medications will be recorded on the 
Concomitant Medication CRF.  A blood draw for antibody testing will be performed and handled per 
specified procedures agreed upon with the investigational site and core laboratory. 
 
6.4 
Intraoperative Procedures and Evaluations 
 
All subjects will undergo the same intraoperative investigational evaluations.  Intraoperative is defined as 
the time interval from when the subject enters the surgical suite until the subject exits the surgical suite. 
 
Subjects undergoing the open elective cardiothoracic, abdominal, and orthopedic lower extremity 
surgeries are eligible for enrollment into the clinical investigation.  The Investigator will perform the 
surgery per his or her standard procedures, including conventional methods of hemostasis (pressure, 
ligature, cautery, etc.). 
 
6.4.1 
Intraoperative Inclusion Criteria 
 
A subject must then meet all of the following intraoperative inclusion criteria: 
 
• 
Subject does not have an active or suspected infection at the surgical site; 
• 
Subject undergoing cardiothoracic surgery with anticoagulation must have anticoagulation 
reversed prior to TBS identification and treatment; 
• 
Subject in whom the Investigator is able to identify a TBS for which any applicable conventional 
means for hemostasis are ineffective or impractical; and 
• 
Subject has a TBS with an SBSS score of 1, 2, or 3. 
 
If all of these intraoperative eligibility criteria are met, then the subject is formally randomized and 
enrolled into the clinical investigation (unless the subject is a lead-in subject; all lead-in subjects will 
receive HEMOBLAST™). 
 
6.4.2 
Randomization and Hemostat Application 
 
At the start of each surgical procedure, a single HEMOBLAST™ device and a single G+T device will 
both be prepared per the respective Instructions for Use (unless the subject is a lead-in subject; all lead-in 
subjects will have a single HEMOBLAST™ device prepared). The preparation time for both devices will 
be recorded for the TTH Population subjects.   
 
Randomization will be performed through sequentially numbered sealed envelopes.  Four-hundred 
subjects (TTH Population) will be randomized to receive HEMOBLAST™ or G+T in a 2:1 ratio: 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 26 of 56 
 
• 
267 subjects will be randomized to receive HEMOBLAST™; and 
• 
133 subjects will be randomized to receive G+T. 
 
There will be a maximum of 50 lead-in subjects; these subjects will not be randomized. The first subject 
for each investigator will be treated as a lead-in subject.  These subjects will receive HEMOBLAST™ 
and will be followed for safety only (maximum Full Analysis Population of 450); lead-in subjects will not 
count towards the TTH Population.  Please see Section 12 below for additional detail on subject 
populations. 
 
Randomization will be stratified by surgical indication and will incorporate blocking; additional details of 
randomization and blocking will be included in a separate Randomization Plan. 
 
After randomization and enrollment, the assigned hemostat will be used in the investigational subject; the 
other hemostat will be discarded following institutional procedures. 
 
A study-specific stopwatch will be used to track hemostat application and the times of hemostasis 
evaluation.  The time of initial hemostat application will be considered time 0; at this time, the stopwatch 
will be started by the study coordinator.  The stopwatch will run continuously without stopping.  
 
Hemostasis will be evaluated by the investigator at the following time points until hemostasis has been 
achieved: 
• 
3 minutes; 
• 
6 minutes; and 
• 
10 minutes. 
 
Reapplication of the randomized hemostat will be performed at the 3 minute and 6 minute evaluation time 
points, as described below. 
 
For cardiothoracic procedures, the TBS will be identified after heparin reversal.  Additionally, the TBS 
will not be at the site of a valve implant or at the site of a synthetic graft or patch implant. 
 
HEMOBLAST™ will be applied according to its instructions for use. 
 
1. Peel open the pouches to remove contents with attention to sterile procedures. 
2. Remove cap using a twisting motion. 
3. Blot excess blood from the target bleeding site with gauze/pad or suction so the hemostatic 
implant material may be applied directly to the source of bleeding.  The wound surface should be 
as dry as possible before application. 
4. Apply hemostatic implant material to the source of bleeding by squeezing the bellows.  Enough 
implant material should be applied to cover the entire source of bleeding.   
5. Immediately use a wet laparotomy pad to hold the hemostatic material at the target bleeding site 
using wound appropriate pressure to conform the powder to the source of bleeding. 
6. Maintain the hemostatic material at the target bleeding for approximately three minutes.  Gently 
lift the laparotomy pad and inspect the area. 
7. If hemostasis has not been achieved, repeat steps 3-6 or use an alternate method of hemostasis 
treatment. 
8. Discard any unused product after opening. 
 
HEMOBLAST™ contraindications include: 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 27 of 56 
 
• 
Do not inject directly into the blood vessels. 
• 
Do not apply HEMOBLAST™ Bellows in the absence of active blood flow, e.g., while the vessel 
is clamped or bypassed.  Extensive intravascular clotting and even death may result.  
• 
Do not use HEMOBLAST™ Bellows for treatment of severe or brisk bleeding. 
• 
Do not administer to patients with known allergies or hypersensitivity to materials of porcine or 
bovine origin. 
• 
To avoid risk of allergic-anaphylactoid reaction and/or thromboembolic events, which may be 
life-threatening, do not inject HEMOBLAST™ Bellows into a vessel or tissue. 
• 
Do not use in the closure of skin incisions because it may interfere with the healing of the skin 
edges due to mechanical interposition of the powder. 
 
After randomization, G+T will be applied to the TBS per the Instructions for Use for subjects assigned to 
this treatment group.   
 
6.4.3 
Bleeding Severity and Hemostasis Evaluations 
 
Bleeding severity and hemostasis will be assessed using the SBSS. 
 
An SBSS score will be assigned at the following time points until hemostasis is achieved: 
 
• 
Baseline – when evaluating intraoperative eligibility; 
• 
3 minutes; 
• 
6 minutes; and 
• 
10 minutes. 
 
An SBSS score of 0 is equivalent to hemostasis.  All other SBSS scores are considered failure of 
hemostasis.  See below in Table 6. 
 
Table 6.  Bleeding Severity and Hemostasis 
SBSS Score 
0 
1 
2 
3 
4 
5 
Verbal 
Descriptor 
None 
Minimal 
Mild 
Moderate 
Severe; not 
immediately 
life-
threatening 
Extreme; 
immediately 
life-
threatening 
Visual 
Descriptor 
Dry 
Oozing 
Pooling 
Flowing 
Streaming 
Gushing 
Expected 
Intervention(s) 
None 
Manual 
pressure, 
cautery, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
adjuvant 
hemostat(s) 
Manual 
pressure, 
cautery, 
suture, 
staples, tissue 
repair 
Manual 
pressure, 
cautery, 
suture, 
staples, tissue 
repair 
Maximum 
Expected 
ACS-ATLS 
Shock Risk 
Class 
1 
1 
1 
2 
3 
4 
Hemostasis 
Yes 
No 
No 
No 
No 
No 
 
In cases where the target bleeding site is still bleeding at the 3 minute or 6 minute assessment time points, 
repeat application of the randomized hemostat will be performed. 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 28 of 56 
 
 
In cases where hemostasis is not achieved by 10 minutes, the Investigator may use whatever means 
necessary in order to control bleeding, except for any hemostatic products containing thrombin or 
aprotinin (Thrombin-JMI, Evithrom, Floseal, Tisseel, Evicel, Tachosil, Evarrest).  Recothrom should not 
be used in subjects randomized to receive HEMOBLAST™, but may be used in subjects randomized to 
the G+T arm. 
 
In any case where hemostasis is initially achieved but bleeding recurs prior to subject closure, the event 
will be documented and treated as an adverse event, and the time of observation of the re-bleed will be 
recorded.   
 
6.4.4 
Other Bleeding Sites 
 
For bleeding sites other than the TBS, the Investigator may use any means necessary to control bleeding, 
except for any hemostatic products containing thrombin or aprotinin (Thrombin-JMI, Evithrom, Floseal, 
Tisseel, Evicel, Tachosil, Evarrest).  Recothrom should not be used in subjects randomized to receive 
HEMOBLAST™, but may be used in subjects randomized to the G+T arm. 
 
The Investigator may also use any of the remaining randomized hemostat on these bleeding sites. 
 
6.4.5 
Intraoperative Data Collection 
 
The following data will be recorded on the Intraoperative CRF: 
 
• 
Surgical procedure(s); 
• 
Preparation times for each device; 
• 
Description of TBS; 
o Location, 
o Tissue type, 
o Conventional means for hemostasis (pressure, suture, cautery, etc.), 
• 
Confirmation of intraoperative eligibility criteria; 
• 
Approximate dimensions of target bleeding site; 
• 
SBSS score at baseline and each evaluation time point (3, 6, and/or 10 minutes) until hemostasis 
is achieved; 
• 
Randomization; 
o Randomization envelope number, 
o Time of randomization, 
o Treatment arm and device lot/batch number data, 
• 
Hemostat application; 
o Application amount 
o HEMOBLAST™ application amount will be approximated by indicating the amount of 
powder left in the bellows after application 
o G+T application amount will be documented by approximating the dimensions of 
Surgifoam sponge applied 
• 
Rescue treatment(s), if any; 
• 
Use of other hemostatic agent(s), if any; 
• 
Skin open and skin closure times; 
• 
Intraoperative administration of blood products; 
• 
Total intraoperative estimated blood loss; 
• 
Incidence of any device deficiencies; and 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 29 of 56 
 
• 
Incidence of any complications or adverse events. 
 
The Concomitant Medication, Adverse Event, and Device Deficiency CRFs will be completed as 
applicable. 
 
Table 7 below shows a timeline of intraoperative procedures. 
 
Table 7.  Timeline for Intraoperative Procedures* 
Time Point (Minutes:Seconds) 
Study Procedures or Assessments 
Prior to 00:00 
• 
Prepare both hemostatic devices and record time of 
preparation 
• 
Identify Target Bleeding Site (TBS) 
• 
Assign SBSS score 
• 
Perform randomization (unless lead-in subject) 
00:00 
• 
Start stop-watch 
• 
Apply HEMOBLAST™ or G+T 
03:00 
• 
Assign SBSS score 
 
If SBSS = 0 
• 
Intraoperative efficacy evaluation completed 
 
If SBSS is NOT 0 
• 
Re-apply HEMOBLAST™ or G+T 
06:00 
• 
Assign SBSS score 
 
If SBSS = 0 
• 
Intraoperative efficacy evaluation completed 
 
If SBSS is NOT 0 
• 
Re-apply HEMOBLAST™ or G+T 
10:00 
• 
Assign SBSS score 
 
If SBSS = 0 
• 
Intraoperative efficacy evaluation completed 
 
If SBSS is NOT 0 
• 
Rescue treatment 
* Assuming subject meets all intraoperative eligibility criteria 
 
The Concomitant Medication, Reoperation, and Adverse Event CRFs will be completed as applicable. 
 
6.5 
Postoperative Procedures and Evaluations 
 
All subjects will undergo the following assessments within 24 hours postoperatively, which will be 
recorded on the Postoperative CRF: 
 
• 
CBC (Laboratory CRF); 
• 
Postoperative visit date; 
• 
Coagulation status (Laboratory CRF); 
• 
Chemistry panel (Laboratory CRF); 
• 
Clinical signs or symptoms of bleeding; 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 30 of 56 
 
• 
Any administration of blood products; 
• 
Incidence of reoperation for bleeding; and 
• 
Incidence of any complications or adverse events. 
 
The Laboratory CRF will be completed and the Concomitant Medication, Reoperation, and Adverse 
Event CRFs will be completed as applicable. 
 
6.6 
Follow-Up Procedures and Evaluations 
 
All subjects will undergo the following assessments 6 weeks ± 2 weeks postoperatively, which will be 
recorded on the Follow-Up CRF: 
 
• 
Date of hospital discharge; 
• 
Signs or symptoms of bleeding; 
• 
Blood draw for antibody testing; 
• 
Incidence of reoperation for bleeding; and 
• 
Incidence of any complications or adverse events. 
 
The Concomitant Medication, Reoperation, and Adverse Event CRFs will be completed as applicable.  A 
blood draw for antibody testing will be performed and handled per specified procedures agreed upon with 
the investigational site and core laboratory. 
 
6.7 
Discontinuation Procedures and Documentation 
 
The Discontinuation CRF should be completed in the following cases: 
 
• 
Subject has completed the 6 week follow up;  
• 
Subject withdrawal;  
• 
Subject death; or  
• 
Subject loss to follow-up. 
 
The reason for discontinuation and the date of discontinuation will be noted on the Discontinuation CRF. 
 
6.8 
Reoperation Documentation 
 
In cases of reoperation, the following evaluations will be recorded on the Reoperation CRF: 
 
• 
Date of reoperation; 
• 
Description of surgical procedure; 
• 
Reason for reoperation; and 
o If for bleeding, an Adverse Event CRF will need to be completed 
• 
Previous target bleeding site assessments, if able; and 
o If hemostat (HEMOBLAST™ or G+T) is visually present, 
o If the site is still bleeding, 
o Any other significant findings (e.g., infection, adhesion, etc.). 
 
7 
ADVERSE EVENTS 
 
7.1 
General 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 31 of 56 
 
 
An adverse event (AE) is defined according to the European Standard EN ISO 14155 as ‘any untoward 
medical occurrence in a subject’.  An adverse event related to a device is defined as an ‘adverse device 
effect’ (ADE) and is defined as ‘any untoward and unintended response to an investigational medical 
device’. 
 
An adverse event or an adverse device effect may be mild, moderate or severe and are usually 
unexpected.  
 
A device deficiency is defined as the inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance, which may include device malfunctions, use errors and 
inadequate labeling.  
 
All adverse events, adverse device effects, and or device deficiencies, either observed by the Principal 
Investigator or reported by the subject, must be reported to the Sponsor/Sponsor representative.  To report 
an adverse event or adverse device effect or device deficiency, the Principal Investigator will complete an 
adverse event report form or relevant form located in the Case Report Form.  The report will include the 
following information: nature, severity, date of onset, duration, course and history of the adverse 
event/adverse device effect and causality. The subject will be questioned about any adverse event(s) and 
adverse device effect(s) at each visit. 
 
Expected adverse events and anticipated adverse device effects are included in Section 13. 
 
7.2 
Adverse Event Documentation 
 
Adverse events will be documented by the Principal Investigator on the appropriate source document(s) at 
the investigational site and also on the Adverse Event CRF.  Adverse events are to be recorded and dated 
according to when they are first observed.  The subsequent treatment(s) should also be documented.  The 
following will be recorded on the Adverse Event CRF: 
 
• 
Accepted medical term for the event; 
• 
Description of the event; 
• 
Date of onset; 
• 
Date of resolution, if applicable; 
• 
Outcome; 
• 
Treatment(s)/action(s) taken; 
• 
Severity; 
• 
Relationship to the investigational device; and 
• 
Determination of reportability (see Reporting Section below). 
 
The severity of the event will be determined by the Principal Investigator using the following definitions: 
 
• 
Mild: the symptoms are transient, barely perceptible by the subject and do not hinder normal 
activity; no treatment is usually prescribed to reduce these symptoms; 
• 
Moderate: the symptoms are sufficiently severe to provoke discomfort in the subject and 
sufficiently uncomfortable to prevent normal activity; a treatment may be required; or 
• 
Severe: the symptoms considerably modify the normal course of the subject’s activities or are 
disabling or are life-threatening; the treatment studied should be suspended; a treatment for the 
symptoms is prescribed. 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 32 of 56 
 
The relationship to the investigational device will be determined by the Principal Investigator using the 
following definitions: 
 
• 
Not related: the adverse event is due to the underlying disease state or is due to concomitant 
medications or therapy not related to the use of the device; 
• 
Possibly related: the adverse event has a reasonable temporal relationship to the use of the device 
but alternative etiology is equally or more likely compared to the potential relationship to the use 
of the device; 
• 
Probably related: the adverse event has a strong temporal relationship to the use of the device and 
alternative etiology is less likely compared to the potential relationship to the use of the device; or 
• 
Definitely related: the adverse event has a strong temporal relationship to the use of the device, 
follows a known response pattern and cannot reasonably be explained by known characteristics of 
the subject’s clinical state or other therapies. 
 
The expectedness of the adverse event will be determined by the Principal Investigator as: 
 
• 
Anticipated; or 
• 
Unanticipated. 
 
7.3 
Reporting 
 
A serious adverse event (SAE) is defined as an adverse event that: 
 
• 
Led to death; 
• 
Led to a serious deterioration in the health of the subject, that either resulted in a life-threatening 
illness or injury, or a permanent impairment of a body structure or a body function, or in-patient 
hospitalization or prolongation of existing hospitalization, or resulted in medical or surgical 
intervention to prevent life-threatening illness or injury or permanent impairment to a body 
structure or a body function; or 
 
A serious adverse device effect (SADE) is defined as an adverse device effect that has resulted in any of 
the consequences characteristic of a serious adverse event or that might have led to any of these 
consequences if suitable action had not been taken or intervention had not been made or if circumstances 
had been less opportune. 
 
An unanticipated [serious] adverse device effect (UADE/USADE) is any serious adverse effect on health 
or safety, any life-threatening problem or death caused by, or associated with a device, if that effect, 
problem, or death was not previously identified in nature, severity, or degree of incidence in the protocol; 
or any other unanticipated serious problem associated with a device that relates to the rights, safety, or 
welfare of subjects. 
 
All SAEs, SADEs, and UADEs must be reported to the Sponsor representative within 24 hours of the 
Principal Investigator becoming aware of it.   
 
There are two methods of reporting.  The first is to complete and save the Serious Adverse Event eCRF 
within 24 hours of the Principal Investigator becoming aware of the SAE, SADE, or UADE. 
 
The second method of reporting is to contact the Sponsor representative for event reporting: 
 
Contact Name: Rachel Hoffman 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 33 of 56 
 
Telephone Number: +1 404 702 9253 (24 hour availability) 
  
E-Mail: rhoffman@namsa.com 
 
 
The Principal Investigator should institute appropriate therapeutic and follow-up measures in accordance 
with good medical practice and record them in the subject’s source documentation and on the Adverse 
Event CRF.  It is the responsibility of the Principal Investigator to inform the appropriate personnel as 
required by IRB policy. 
 
For SAEs that are unresolved, the Principal Investigator will continue to follow the event to resolution per 
standard medical care.  Serious adverse event follow-up information regarding resolution will be provided 
to the Sponsor representative until the subject completes the 6 week follow-up and is discontinued from 
the clinical investigation.  If the subject is discontinued prior to resolution of the event, the Principal 
Investigator will continue to follow the event until the event is deemed medically stable or resolved.  
Follow-up information after subject discontinuation will not need to be provided to the Sponsor 
representative. 
 
For SADEs and UADEs, the event will be followed until resolution and follow-up information will be 
provided to the Sponsor representative. 
 
7.4 
Regulatory Authority and Institutional Review Board Notifications 
 
The Sponsor shall report results of their evaluations of UADEs to the FDA, all reviewing IRBs, and all 
participating Investigators within 10 business days after the Sponsor/Sponsor representative first receives 
notice of the event. 
 
Further, the Sponsor shall report results of their evaluations of UADEs to the Regulatory Authority and 
all applicable reviewing IRBs, and all participating Investigators within 10 business days after the 
Sponsor/Sponsor representative first receives notice of the event. 
 
Please see Tables 10 and 11 below for reporting requirements and associated timelines. 
 
8 
INDEPENDENT DATA MONITORING COMMITTEE 
 
An Independent Data Monitoring Committee (IDMC) will be formed to review data from the clinical 
investigation to evaluate the safety and efficacy of the investigational device.  The IDMC will be formed 
prior to subject enrollment and the names, affiliations, and academic backgrounds of all members will be 
provided to the Regulatory/Competent Authority. 
 
The members of the IDMC are responsible for safeguarding the interests of study participants, assessing 
the safety and efficacy of study procedures, and reviewing the overall conduct of the clinical 
investigation.  The IDMC will review clinical investigation data to evaluate study conduct, investigational 
device safety, and scientific validity and integrity of the investigation. 
 
The IDMC will provide recommendations regarding the implementation and progress of clinical 
investigation, including continuation, suspension and/or termination of the clinical investigation.  A 
separate charter for the IDMC will define and describe: 
 
• 
Roles and responsibilities; 
• 
Membership; 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 34 of 56 
 
• 
Frequency of meetings; and 
• 
Documentation and reporting. 
 
A separate CEC (Clinical Events Committee) will be formed to review all SAEs and corresponding data 
for each SAE.  The CEC will be formed prior to subject enrollment and the names, affiliations, and 
academic backgrounds of all members will be provided to the Regulatory Authority. 
 
The members of the CEC will be responsible for reviewing and adjudicating SAEs for relatedness to the 
hemostatic device and expectedness.  A separate charter for the CEC will define and describe: 
 
• 
Roles and responsibilities; 
• 
Membership; 
• 
Frequency of meetings; 
• 
Adjudication process; and 
• 
Documentation and reporting. 
9 
DATA COLLECTION 
 
9.1 
Completion of Case Report Forms 
 
Prior to the start of the clinical investigation, the Sponsor representative will provide the Principal 
Investigator and designated investigational site staff with training on electronic CRF completion 
procedures.  The Principal Investigator will be responsible for the timing, accuracy, and completeness of 
CRFs for each individual subject.  The personal data recorded on all paper and electronic documents will 
be regarded as confidential.   
 
The Principal Investigator will maintain a separate list of all subjects entered into the clinical 
investigation showing each subject’s name, date of birth, and assigned subject number (for identification 
purposes). A Subject Identification Log will also be provided in the Investigation Site File to record the 
subject’s initials and assigned subject number. 
 
9.2 
Source Documentation 
 
Source documents are where clinical investigation information for subjects are first recorded.  Data 
collected for the clinical investigation must be supported by source documents, and may include, but is 
not limited to, subject medical records, hospital charts, operative reports, laboratory and diagnostic test 
reports, and study worksheets.   
 
9.3 
Retention of Clinical Investigation Documentation 
 
Clinical investigation records will be stored in a confidential manner so as to protect the confidentiality of 
subject information.  All records related to this clinical investigation will be retained in appropriate 
investigation files. 
 
The Principal Investigator is responsible for retaining all copies of the records for a period of no less than 
5 years from the latter of the two dates: the date on which the clinical investigation is 
completed/terminated or the date that records are no longer required for the purposes of supporting a 
marketing application.  In all cases, the Principal Investigator must contact the Sponsor prior to disposing 
of any records related to the clinical investigation.  Included in records to be maintained are the signed 
Clinical Investigational Plan, copies of the Case Report Forms, signed consent forms, IRB approval 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 35 of 56 
 
letters, product accountability records, correspondence concerning the clinical, and any other documents 
to identify the subjects.  
 
The Sponsor must approve the destruction of any investigational records. 
 
In addition, if the Principal Investigator moves/retires, etc., he/she should provide the Sponsor with the 
name and address of the person who will look after and be responsible for the clinical investigation 
related records. 
 
9.4 
Training 
 
Principal Investigators and investigational site staff will be trained on the clinical investigation and the 
specific tasks to which they are delegated.  Investigational site staff will also have documented training on 
applicable regulations and guidances, including Good Clinical Practice. 
 
Further, investigators (Principal Investigators and sub-investigators responsible for enrolling study 
subjects and applying the investigational and control devices) will have training on use of the 
investigational device, control device, and the SBSS.  Investigator training procedures and requirements 
are detailed within the Investigator Training Plan (Appendix D). 
 
10 
TERMINATION OF THE CLINICAL INVESTIGATION 
 
10.1 Subject Withdrawals and Discontinuation 
 
During the course of this clinical investigation, subjects will be or may elect to withdraw from 
investigation participation for any of the following reasons: 
 
• 
Subject’s withdrawal of consent; 
• 
Any unexpected adverse device effect which is, in the opinion of the Principal Investigator, 
related to the device and will endanger the well-being of the subject if the treatment is continued; 
• 
The development of any undercurrent illness(es), infection(s) or condition(s) that might interfere 
with the Clinical Investigational Plan; or 
• 
Any problem deemed by the Principal Investigator and/or Sponsor to be sufficient to cause 
discontinuation. 
 
All subjects discontinued from the clinical investigation due to an UADE, directly related to the clinical 
investigation, will be treated until the effect resolves. The Principal Investigator will clearly document the 
date and reason(s) for subject withdrawal in Discontinuation CRF. 
 
Subjects who are withdrawn will not be replaced if they have received the investigational or control 
device. If possible, any procedures or assessments planned for the subject on withdrawal from the clinical 
investigation should be performed when intention to withdraw the subject is announced. 
 
Subjects who are withdrawn prior to receiving investigational or control device will be replaced. 
 
10.2 Early Termination of the Clinical Investigation 
 
Both the Sponsor and Principal Investigator reserve the right to terminate the clinical investigation at any 
time.  Should this be necessary, the procedures will be arranged on an individual site basis after review 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 36 of 56 
 
and consultation by both parties.  In terminating the clinical investigation, the Sponsor and the Principal 
Investigator will assure that adequate consideration is given to the protection of the subjects’ interests. 
 
11 
DATA MANAGEMENT 
 
All data will be housed in a validated database program.  All data queries will be resolved with the 
assistance of monitoring and investigational site staff.  
 
On resolution of all data queries, the database will be closed and data listings, summary tables, graphical 
output and descriptive statistics produced.  All data listings, except SAEs (the final report will include the 
CEC adjudications for all SAEs), for inclusion into the final report, will be subject to sample quality 
control checks against the Case Report Forms.   
 
Once all the subject data has been collected, the analysis and reporting will be conducted. Any data 
existing for subjects who have not received treatment, will not be used in the analysis.  Details of these 
subjects will, however, be referenced in the final report. 
 
Any data existing for subjects who have received the investigational or control device, who withdraw 
voluntarily or who are withdrawn from the clinical investigation, will be used in the final analysis.  The 
inclusion of partial data will be documented in the final report. The final report will be the responsibility 
of Biom’Up. 
 
12 
STATISTICS 
12.1 Overview 
  
12.1.1 Primary Efficacy Endpoint 
 
The primary efficacy endpoint of this clinical investigation is non-inferiority of HEMOBLAST™ relative 
to G+T for success at achieving hemostasis within 6 minutes.  The definition of the primary endpoint is 
provided in Table 7. 
 
12.1.2 Secondary Efficacy Endpoints 
 
Pre-defined secondary efficacy endpoints and hypotheses that will be assessed at study completion will 
be: 
 
1. Superiority of HEMOBLAST™ relative to G+T in mean preparation time from the opening of 
package to product being ready to use; 
2. Non-inferiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 3 
minutes; 
3. Superiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 6 
minutes; and 
4. Superiority of HEMOBLAST™ relative to G+T for success at achieving hemostasis within 3 
minutes. 
  
The definitions of each secondary endpoint are listed in Table 8. 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 37 of 56 
 
Table 8: Primary and secondary endpoints and hypotheses 
Endpoint 
and 
Hypothesis 
Definition of Endpoint 
Primary Efficacy Endpoint and Hypothesis 
Non-inferiority 
for TTH within 6 
minutes 
Binary indicator of patient achieving hemostasis within 6 minutes. Time-to-hemostasis is defined as the 
interval from the application of study intervention until investigator deemed hemostasis. Hemostasis 
will be assessed via the SBSS. For the primary endpoint, a subject will be considered a success if 
complete hemostasis (SBSS of 0) is achieved and maintained within 6 minutes without the use of an 
additional hemostatic product or surgical rescue. 
Secondary Endpoints and Hypotheses 
Superiority 
for 
Preparation Time 
Mean preparation time, defined as the average time from the opening of package to product being ready 
to use (measured in minutes and seconds). 
Non-inferiority 
for TTH within 3 
minutes 
Binary indicator of subject achieving hemostasis within 3 minutes. Time-to-hemostasis is defined as the 
interval from the application of study intervention until investigator deemed hemostasis. For this 
secondary endpoint, a subject will be considered a success if complete hemostasis (SBSS of 0) is 
achieved and maintained within 3 minutes without the use of an additional hemostatic product or 
surgical rescue.  
Superiority 
for 
TTH 
within 
6 
minutes 
Binary indicator of subject achieving hemostasis within 6 minutes. Time-to-hemostasis is defined as the 
interval from the application of study intervention until investigator deemed hemostasis. For this 
secondary endpoint, a subject will be considered a success if complete hemostasis (SBSS of 0) is 
achieved and maintained within 6 minutes without the use of an additional hemostatic product or 
surgical rescue. 
Superiority 
for 
TTH 
within 
3 
minutes 
Binary indicator of subject achieving hemostasis within 3 minutes.  Time-to-hemostasis is defined as 
the interval from the application of study intervention until investigator deemed hemostasis.  For this 
secondary endpoint, a subject will be considered a success if complete hemostasis (SBSS of 0) is 
achieved and maintained within 3 minutes without the use of an additional hemostatic product or 
surgical rescue. 
 
 
12.1.3 Safety Outcomes 
 
Endpoints used to characterize the safety profile include the rate of occurrence of all AEs and SAEs, 
reoperation rate due to bleeding, mean volume of intraoperative transfusions, total operative time, mean 
duration of hospitalization, intraoperative blood product administration, and post-operative blood product 
administration. 
 
12.1.4 Individual Subject and Overall Study Success 
 
Individual subject success will be defined as hemostasis of the target bleeding site within 6 minutes of 
hemostat application.  The proportion of subjects, overall, and in each surgical indication, meeting this 
success criterion will be estimated and a 95% confidence interval for the true proportion of subjects 
meeting the success criteria will be presented.   
 
Overall study success will be defined as non-inferiority of HEMOBLAST™ relative to G+T in the 
proportion of subjects achieving hemostasis within 6 minutes of hemostat application.  
 
12.2 General Analysis Considerations 
 
All statistical analyses will be performed using SAS® and R.  Unless otherwise specified, all continuous 
endpoints will be summarized using descriptive statistics, which will include the number of subjects (n), 
mean, standard deviation, median, minimum, and maximum.  All categorical endpoints will be 
summarized using frequencies and percentages.   
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 38 of 56 
 
12.2.1 Analysis Populations 
 
Safety analyses will be performed on the Full Analysis Population, defined as all subjects who were 
randomized into the study and received study intervention and all lead-in subjects.  Efficacy analyses will 
be conducted on the time to hemostasis (TTH) Analysis Population, defined as all subjects who were 
randomized, received study intervention, and had a TTH assessment recorded regardless of whether the 
measurement was censored (defined as the use of an additional hemostatic product or surgical rescue 
prior to the end of observation time, or failing to achieve and maintain complete hemostasis prior to the 
end of observation time).  Data summaries will be based on the intervention received, regardless of which 
intervention was randomly assigned. 
 
12.2.2 Handling of Missing Data 
 
In primary analyses, missing TTH values will not be imputed. All values right censored prior to 6 minutes 
will be considered treatment failures for the purpose of the primary analysis.  Further sensitivity analyses 
for the impact of potential missing data will be defined in the Statistical Analysis Plan (SAP). 
 
12.2.3 Subgroup Analyses 
 
Descriptive analyses of safety and efficacy data will be presented by surgery type. The primary efficacy 
endpoint, as well as all secondary efficacy endpoints and safety outcomes will be presented by surgery 
type. Estimates of the distribution of TTH over a maximum follow-up of 10 minutes will be computed 
using the Kaplan-Meier method, stratified by surgery type. Kaplan-Meier estimates for the probability of 
continued bleeding at all scheduled assessment times (3 minutes, 6 minutes, and 10 minutes) will be 
displayed on each plot along with corresponding 95% confidence intervals.  Additionally, the primary 
efficacy endpoint, as well as all secondary efficacy endpoints and safety outcomes will be presented 
stratified by: 
 
• 
The number of interventions (separate applications of randomized hemostat); 
• 
Baseline SBSS score; and 
• 
Abnormal versus normal coagulation values. 
 
The study will recruit patients undergoing elective surgery.  Based upon this and the inclusion/exclusion 
criteria to be implemented, it is assumed that patients with abnormal coagulation studies will not be 
randomized and treated.  In the unlikely event that patients with abnormal coagulation studies are present, 
a secondary analysis of the primary endpoint considering only those subjects with normal coagulation 
studies will also be conducted.  Further, to assess the robustness of the primary endpoint with respect to 
possible imbalances in the frequency of patients with abnormal studies by treatment arm, a “worst-case” 
sensitivity analysis assuming all randomized and treated subjects in the HEMOBLAST™ arm with 
abnormal studies are treatment failures for the primary endpoint (TTH greater than 6 min) while all 
randomized and treated subjects in the G+T arm with abnormal studies are treatment successes (TTH less 
than 6 min).  These subgroup and sensitivity analyses will be presented along with the primary results 
conducted on the TTH Population defined in Section 12.2.1. 
 
12.2.4 Accounting for Multiple Comparisons 
 
The primary analysis comparing the probability of TTH within 6 minutes in subjects receiving 
HEMOBLAST™ to those receiving G+T will be conducted to maintain an overall 0.025 (one-sided) 
significance level accounting for one interim analysis and one final analysis (see Sections 12.4.1 and 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 39 of 56 
 
12.4.2).  The exclusion of a >10% difference in the probability of TTH at 6 minutes will be indicated by 
the lower limit of a 95% confidence interval for the adjusted difference in binomial proportions 
(HEMOBLAST™ – G+T). All reported inference (confidence intervals and p-values) will account for the 
planned interim analysis.  
 
Adjustment for multiple comparisons when assessing secondary endpoints will be performed using a 
fixed sequence closed testing procedure. The experiment-wise Type I error rate will be controlled in the 
strong sense at a (two-sided) 5% significance level. In a fixed sequence testing procedure, the formal 
inferential testing can proceed to the next step only when statistical significance is declared in the current 
step. If the testing sequence is stopped, the remaining endpoints in the testing sequence will be considered 
exploratory. Furthermore, any comparisons that are not presented in the a priori specified testing 
procedure will also be considered exploratory. The fixed sequence testing procedure will be employed 
among the primary and secondary endpoints in the order presented below:    
 
1) Primary endpoint: Success at achieving hemostasis within 6 minutes for the first treated bleeding 
site (comparable efficacy of HEMOBLAST™ relative to G+T, evaluated using a 10% non-
inferiority margin); 
2) Secondary endpoint: The difference between arms in mean preparation time, defined as the time 
from the opening of package to product being ready to use (measured in minutes and seconds); 
3) Secondary endpoint: Success at achieving hemostasis within 3 minutes for the first treated 
bleeding site (comparable efficacy evaluated using a 10% non-inferiority margin); 
4) Secondary endpoint: Success at achieving hemostasis within 6 minutes for the first treated 
bleeding site (superiority of HEMOBLAST™ relative to G+T); and 
5) Secondary endpoint: Success at achieving hemostasis within 3 minutes for the first treated 
bleeding site (superiority of HEMOBLAST™ relative to G+T). 
 
12.2.5 Data Transformations 
 
No transformations of data are planned. 
 
12.2.6 Subject Disposition and Characteristics 
 
The number of subjects randomized to each treatment arm will be tabulated and a flow diagram 
describing the disposition of subjects will be constructed. Demographic variables will include age 
(continuous and by age category [categorized by decade of life]), sex, race, ethnicity, height, and weight.  
Baseline disease characteristics will include reason for surgery and related co-morbidities. All continuous 
endpoints will be summarized using descriptive statistics, that will include the number of subjects (n), 
mean, standard deviation, median, minimum, and maximum.  All categorical endpoints will be 
summarized using frequencies and percentages. 
 
12.2.7 Subject Compliance 
 
Because the study device will be applied by the study investigator during a single surgery, subject 
compliance with completing the efficacy evaluation is not an issue and will not be reported.  Subject 
compliance with completing the follow-up visit will be reported. 
 
12.2.8 Protocol Deviations 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 40 of 56 
 
Eligibility criteria that were not met will be listed along with whether or not an exception was granted.  
Important protocol deviations will be summarized by treatment group.  Important protocol deviations are 
defined as: 
 
- 
Any unauthorized protocol deviations that result in a significant added risk to the study subject; 
- 
Non-adherence to eligibility criteria without prior Sponsor approval; 
- 
Non-adherence to good clinical practices, FDA regulations, and/or ICH guidelines (e.g., failure to 
obtain proper informed consent or failure to report SAEs); 
- 
A high frequency of unauthorized non-adherence to study procedures or schedules that do not 
involve eligibility; 
- 
Development of withdrawal criteria during the study without corresponding subject withdrawal; 
- 
Receipt of a prohibited concomitant medication by a subject; and 
- 
Protocol deviations will be summarized in tables produced by the Medical Monitor or Clinical 
Research Associate. 
 
12.3   Analytic Methods  
 
12.3.1 Analysis of Primary and Secondary Efficacy Endpoints 
 
12.3.1.1 Analysis Population 
 
Efficacy analyses will be conducted on the TTH Population, defined as all subjects who were 
randomized, received study intervention, and had a TTH assessment recorded regardless of whether the 
measurement was censored.  Lead-in subjects are not part of the TTH Population. 
 
12.3.1.2 Methods of Analysis 
 
The primary efficacy endpoint is the difference in the probability of TTH within 6 minutes comparing 
HEMOBLAST™ to G+T.  The lower bound of the 95% confidence interval for the difference in binomial 
probabilities will be used to assess comparable efficacy.  The primary efficacy analysis will be conducted 
on data from the first identified bleeding site for each subject. The estimated difference in the probability 
of TTH at 6 minutes between treatment arms will be adjusted for surgical indication by weighting the 
stratum-specific differences in observed proportions using Cochran-Mantel-Haenszel weighting.18   The 
trial seeks to establish comparable efficacy based upon a non-inferiority margin of 10% for the difference 
in the probability of TTH within 6 minutes comparing HEMOBLAST™ to G+T (HEMOBLAST™– 
G+T). Letting θ denote the true difference in the probability of hemostasis at 6 minutes between  
HEMOBLAST™ to G+T, the trial will test the null hypothesis H0: θ  ≤ -0.10 vs. the alternative 
hypothesis HA : θ > -0.10 using a one-sided level 0.025 test.  The null hypothesis of inferiority will be 
rejected and comparable efficacy will be established if the resulting lower bound of the 95% confidence 
interval for θ is greater than -0.10.  Comparable efficacy will be evaluated using a group sequential 
testing design as described in Section 12.4 with stopping boundaries defined to ensure a maximum overall 
1-sided significance level of 0.025.  Following the completion of the trial, a confidence interval for the 
estimated difference in the probability of hemostasis at 6 minutes will be computed using the Cochran-
Mantel-Haenszel estimator and asymptotic variance estimate in combination with the repeated confidence 
interval method.19  Estimates of the distribution of TTH over a maximum follow-up of 10 minutes will be 
computed based on all available assessment times (3 minutes, 6 minutes, and 10 minutes) using the 
Kaplan-Meier method. 
 
Analyses of the secondary efficacy endpoints will be evaluated only once, at the end of the study, using a 
family-wise 2-sided significance level of 0.05.  Adjustment for multiple comparisons when assessing 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 41 of 56 
 
secondary endpoints will be performed using a fixed sequence closed testing procedure to control the 
family-wise type I error rate at 0.05, as described in Section 12.2.4. The difference in mean preparation 
time will be tested using a linear regression model with stratified adjustment for surgery type. The 
difference in the probability of TTH within 3 minutes will be tested using a general linear model with 
stratified adjustment for surgery type as described above. Wald-based 95% confidence intervals for the 
difference in probability of TTH will be computed.  
 
12.3.2 Analysis of Safety Outcomes 
 
12.3.2.1 Analysis Population 
 
Safety analyses will be conducted on the Full Analysis Population, defined as all subjects who were 
randomized into the study and received study intervention and all lead-in subjects. 
 
12.3.2.2 Methods of Analysis 
 
Summaries of the number and percent of subjects with at least one SAE will be provided.  Comparisons 
of the proportion of subjects experiencing SAEs will be made between treatment arms.   Summaries of 
the number of percent of AEs will be provided for each treatment arm. 
 
Differences in mean overall blood loss, mean volume of intra-operative transfusions, mean total operative 
time, and mean duration of hospitalization will be estimated using linear regression models with stratified 
adjustment for surgery type and separated by surgery type. In all cases, the robust variance estimator will 
be used and a 95% Wald-based interval will be computed. Comparisons of the incidence of re-operation 
(total and reoperation due to bleeding) and the incidence post-surgery bleeding complications will be 
made using a general linear model to estimate the difference in the probability of each outcome after 
stratified adjustment for surgery type.  Comparisons of the incidence of re-operation and the incidence 
post-surgery bleeding complications within each surgery type will be made using a two sample binomial 
test of proportions. 
 
12.4 Interim Analyses 
   
12.4.1 Interim Efficacy/Futility Analysis 
 
A single interim analysis will be performed on the primary efficacy endpoint (difference in the probability 
of TTH within 6 minutes) using data on the TTH Population, defined as all subjects who were 
randomized, received study intervention, and had a TTH assessment recorded regardless of whether the 
measurement was censored.   
 
The study will be monitored by an Independent Data Monitoring Committee (IDMC).  The IDMC will be 
provided with blinded efficacy data at the time of the interim analysis.  Detail of the activities associated 
with the IDMC will be provided in an IDMC Charter. In the following, we provide the description of the 
a priori defined interim analysis plan that will be used in the trial.  
 
In making a decision to recommend early termination of the study, the IDMC shall be guided by a formal 
stopping rule based on the primary efficacy endpoint. The test statistic shall be the estimated difference in 
the probability of TTH within 6 minutes between the HEMOBLAST™ and G+T arms as described in 
Section 12.3.1.2. The clinical trial may only be stopped early either for reasons of futility (the observed 
difference in the probability of TTH within 6 minutes comparing HEMOBLAST™ to G+T is not 
sufficiently high enough to warrant continuation of the trial) or efficacy (the observed difference in the 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 42 of 56 
 
probability of TTH within 6 minutes comparing HEMOBLAST™ to G+T is sufficiently high enough to 
conclude non-inferiority).  
 
The formal stopping boundaries will be determined by futility and efficacy boundaries defined within the 
unified family of group sequential stopping rules.20 In the notation of the latter paper, the stopping rule 
will be based on a one-sided group sequential design testing an upper alternative hypothesis at a level of 
significance α =0.025 with a lower (futility) stopping boundary relationship specified by Pa =0.8 and a  
upper (efficacy) stopping boundary relationship specified by Pd =0.8 (a boundary with conservatism in 
between the Pocock type boundary and an O'Brien-Fleming type boundary).21, 22   
 
The trial will utilize a 2:1 randomization scheme (HEMOBLAST™ : G+T). Randomization will be 
stratified by surgery indication and it is anticipated that accrual to each surgical indication will be roughly 
equal. It is envisioned that one interim analysis will be performed during the monitoring of the study, 
occurring after outcomes have been observed for 240 randomized and treated subjects belonging to the 
TTH Population (approximately 160 subjects treated with HEMOBLAST™ under 2:1 randomization), 
and may continue to a maximal sample size of 400 subjects (approximately 267 subjects treated with 
HEMOBLAST™ under 2:1 randomization). Although the above interim analysis is pre-defined, final 
inference for comparable efficacy will treat the futility boundary as non-binding (implying that the type I 
error rate for the trial will be bounded at or below .025 even if the futility boundary is crossed at the 
interim analysis but the trial continues on).  
 
Under such a monitoring schedule and assuming a probability of TTH within 6 minutes of 88% in both 
the HEMOBLAST™ arm and the G+T arm, a maximal sample size of 400 treated subjects (267 in the 
HEMOBLAST™ arm and 133 in the G+T arm) will provide approximately 80.1% power to determine 
comparable efficacy based upon a 10% non-inferiority margin of absolute difference in the probability of 
TTH within 6 minutes. Of particular note, if the study were to stop in favor of comparable efficacy at the 
interim analysis after 60% of the maximal sample size were accrued, data would be available on 
approximately 160 patients in the TTH Population treated with HEMOBLAST™ plus up to an additional 
50 lead-in subjects.  Assuming equal accrual to each surgical indication this would provide safety data on 
roughly 70 subjects treated with HEMOBLAST™ for each surgery type. 
 
Enrollment will continue in parallel with the interim analysis.  Thus, if the interim analysis supports early 
termination of the clinical investigation, the number of subjects included may be higher than the number 
available at the time of the interim analysis.  All available data for the analysis populations defined above 
will be included in the final analysis and report. 
 
Under the planned schedule of one interim analysis at 240 treated subjects and a assumed 6 min TTH 
success rate of 88% in the G+T arm, Table 9 presents the stopping boundaries at the interim and final 
analysis for the specified stopping rule expressed as the normalized fixed sample z-statistic for testing 
non-inferiority and the corresponding fixed sample p-value.  
 
Table 9: Stopping boundaries for a level 0.025 one-sided design with a single interim analysis (NON-
BINDING FUTILITY (Pa =0.8) AND EFFICACY (Pd =0.8)  occurring at 240 patients, and a maximal 
sample size of 400 patients (2:1 randomization).  The boundaries assume a 88% probability of TTH 
within 6 minutes on the G+T arm and a 10% non-inferiority margin.  Stopping boundaries are 
expressed as the difference in the probability of TTH within 6 minutes (HEMOBLAST™ – G+T). 
 
Analysis 
Total 
Sample Size 
(H, G+T)* 
Futility (lower) 
Stopping Boundary 
Comparable Efficacy 
(upper) Stopping Boundary 
Z-statistic 
P-value 
Z-statistic 
P-value 
1 
240 (160, 80) 
0.788 
0.215 
2.373 
0.009 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 43 of 56 
 
2 
400 (267, 133) 
2.036 
0.021 
2.036 
0.021 
* H : HEMOBLAST™ 
 
Thus, according to the above table, if the observed Z-statistic for testing non-inferiority (Cochran-Mantel-
Haenszel estimate minus the non-inferiority margin, divided by the estimated standard error) is 0.788 or 
lower when 240 subjects have been treated and observed for TTH on the study, the stopping rule would 
suggest that the study be terminated early with a decision that it was futile to continue the trial because 
there was not sufficient evidence that HEMOBLAST™ would be determined to be comparably 
efficacious if the study were to continue. Alternatively, if the observed Z-statistic for testing non-
inferiority is 2.373 or higher when 240 subjects have been treated and observed for TTH on the study, the 
stopping rule would suggest that the study be terminated early with a decision in favor of comparable 
efficacy between the two products. A repeated 95% confidence interval for the stratum-weighted 
difference in proportions, corrected for the stopping rule, will be computed at the completion of the trial. 
In the event that true probability of TTH within 6 minutes for G+T arm is observed to be different from 
88% or the timing of the interim analysis differs, the stopping boundaries will be adjusted to maintain a 
one-sided type one error rate of 0.025 as described in Section 12.4.3. 
  
 
12.4.2 Sample Size Justification 
 
The sample size for the proposed study is based on a level 0.025 (one-sided) test to exclude a probability 
of TTH within 6 minutes that is 10% less among subjects treated with HEMOBLAST™ compared to 
those treated with G+T.  The maximum number of subjects enrolled will be computed as to provide 
approximately 80.1% power to declare comparable efficacy when the two treatments have the same 
probability of TTH within 6 minutes. The variance estimate in the sample size calculation assumes an 
88% 6 minute hemostasis success rate in both the HEMOBLAST™ and G+T arms. The planned stopping 
rule will implement a single interim analysis after outcome data have been observed on 240 treated 
subjects.  If the study were to continue to the final analysis with a decision in favor of comparable 
efficacy, it is anticipated that efficacy data would be available on 400 treated (approximately 267 patients 
treated with HEMOBLAST™ under a 2:1 randomization scheme).  Assuming equal accrual to each 
surgical indication this would provide efficacy data on roughly 89 subjects treated with HEMOBLAST™ 
for each surgery type. 
 
The variance of a proportion is dependent on the proportion itself.  Hence, power for the study will be 
partially determined by the probability of TTH within 6 minutes on each of the treatment arms.  Under the 
design assumption that the probability of TTH within 6 minutes on the G+T arm is 88%, the study will 
require a maximum of 400 treated subjects to attain approximately 80.1% power to declare comparable 
efficacy based upon a 10% non-inferiority margin.  As discussed in Section 12.4.3, in order to maintain 
approximately 80.1% power should a larger variance be observed, a flexible sample size based on 
statistical information from pooled trial data will be used.23  
 
12.4.3 
Implementation of the Stopping Boundary 
 
Modifications of the stopping rule to account for changes in the schedule of the interim analysis and 
estimates of variability will be made by using the parametric form of the stopping rule as specified above, 
a blinded sample size recalculation will be performed prior to the interim analysis. An independent 
statistical reporting group preparing reports for the IDMC will use the constrained boundaries method as 
implemented in S+SeqTrial® to recalculate the maximal sample size based on the marginal response rate 
observed in the study at the time of the pre-planned interim analysis (marginalized over treatment arms).23 
The one-sided type I error rate for the study will be maintained at 0.025, and the maximal sample size will 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 44 of 56 
 
be adjusted up to maintain 80.1% power provided that the recalculated maximal sample size is 460 treated 
subjects or less within the TTH Population as defined in 12.3.1.1. Further details of the implementation of 
the stopping boundary will be provided in the Statistical Analysis Plan. 
 
13 
RISK/BENEFIT ANALYSIS 
 
13.1 Anticipated Clinical Benefits 
 
It is anticipated that application of the investigational device to a bleeding site will result in a reduced 
time to hemostasis compared to conventional methods of hemostasis (pressure, suture, or cautery).  
Individual subjects may not directly benefit from participation in this investigation.  However, conducting 
this research could contribute to the overall advancement of medical and scientific knowledge and may 
benefit future patients. 
 
13.2 Risks Associated with Participation in the Clinical Investigation 
 
There are possible risks, complications, and discomforts associated with undergoing a surgical procedure.  
There are also additional risks specifically associated with the surgical arm (cardiothoracic, abdominal, 
orthopedic lower extremity). The Investigator will be responsible for discussing these risks, complications 
and discomforts with subjects along with the risks associated with anesthesia.   
 
Adverse events observed during and after the application of a hemostatic agent other than 
HEMOBLAST™ in a large pivotal clinical trial of 309 patients at a greater than 1% frequency included: 
 
• 
Anemia; 
• 
Arrhythmia; 
• 
Atelectasis; 
• 
Confusion; 
• 
Dural tear; 
• 
Edema; 
• 
Fever; 
• 
Fibrillation Atrial; 
• 
Fibrillation Ventricular; 
• 
Heart Failure Right; 
• 
Hemorrhage; 
• 
Hypotension; 
• 
Infection; 
• 
Pleural Effusion 
• 
Pneumonia; 
• 
Rash; 
• 
Respiratory distress; 
• 
Thrombosis Arterial; and 
• 
Urinary Tract Infection. 
 
None of the adverse events that occurred were judged by the surgeon to be “Probably Related” to the use 
of the hemostatic agent. 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 45 of 56 
 
Adverse events observed during and after the application of a hemostatic agent other than 
HEMOBLAST™ in a large pivotal clinical trial of 309 patients at a less than 1% frequency included: 
 
• 
Abscess; 
• 
Acute kidney failure; 
• 
Back pain; 
• 
Bradycardia; 
• 
Cellulitis; 
• 
Cerebrovascular accident; 
• 
Dehiscence; 
• 
Diarrhea; 
• 
Dyspnea; 
• 
Gastritis; 
• 
Hallucination; 
• 
Heart arrest; 
• 
Heel ulcer; 
• 
Hyperglycemia; 
• 
Kidney tubule necrosis; 
• 
Lung edema; 
• 
Myocardial Infarction; 
• 
Nausea; 
• 
Nausea and vomiting; 
• 
Neuropathy; 
• 
Pain; 
• 
Paraesthesia; 
• 
Pneumothorax; 
• 
Rash; 
• 
Skin ulcer; 
• 
Transfusion reaction; 
• 
Urinary Retention; and 
• 
Ventricular Tachycardia. 
 
None of the adverse events that occurred were judged by the surgeon to be “Probably Related” to the use 
of the hemostatic agent. 
 
Risks possibly related to the use of hemostats similar to HEMOBLAST™ include: 
 
• 
Adhesion formation 
• 
Allergy or anaphylaxis 
• 
Blockage of cardiopulmonary bypass system; 
• 
Compromised attachment of orthopedic implants; 
• 
Creutzfeldt-Jakob disease (CJD) agent; 
• 
Increased infection; 
• 
Lack of efficacy  
• 
Nerve compression; 
• 
Thrombosis or thromboembolism 
• 
Transmissible Spongiform Encephalopathies (TSE); and 
• 
Viral disease transmission; 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 46 of 56 
 
 
Hypersensitivity or allergic/anaphylactoid reactions may occur with HEMOBLAST™.  Symptoms 
associated with allergic anaphylactic reactions include: flush, urticaria, pruritus, nausea, drop in blood 
pressure, tachycardia or bradycardia, dyspnea, severe hypotension, and anaphylactic shock. 
 
These reactions may occur in patients receiving HEMOBLAST™ for the first time or may increase with 
repetitive applications of HEMOBLAST™.  In the event of hypersensitivity reactions, discontinue 
administration of HEMOBLAST™.  Mild reactions can be managed with antihistamines. Severe 
hypotensive reactions require immediate intervention using current principles of shock therapy.  
 
Subjects randomized to receive the control are exposed to risks associated with G+T, as described in the 
current device labeling. 
 
Participation in this clinical investigation also presents additional risks or inconveniences.  These may 
include, but are not limited to: 
 
• 
An additional blood draw preoperatively and an additional blood draw at 6-week follow-up for 
antibody evaluation; 
• 
Urine or serum pregnancy test (females of child bearing age) performed preoperatively; 
• 
Additional intraoperative assessments of bleeding severity at 3, 6, and 10 minutes after hemostat 
application; and 
• 
Follow-up visit at 6 ± 2 weeks postoperatively. 
 
There may also be other unforeseen risks. 
 
13.3 Risk/Benefit Analysis 
 
Individual patients may experience no direct benefit from participation in the study.  However, potential 
benefits of HEMOBLAST to be investigated in the study include shorter preparation time, in addition to 
the other endpoints that will be tested for potential superiority as discussed above.  Risk mitigation steps 
have been taken through investigational device specifications and the performance of non-clinical testing 
and a clinical study.  Risk mitigation steps are also implemented in the manufacture and shipment of the 
investigational device. 
 
The Sponsor, Medical Expert, and co-ordinating Investigator have determined that this clinical 
investigation is justified because the potential benefits outweigh the potential risks.  Additionally, an 
IDMC is being put in place to perform continual reviews on the study, including making 
recommendations based on risk/benefit. 
 
13.4 Conduct of Clinical Investigation to Reduce Risk 
 
Further efforts to minimize risk in this clinical investigation will involve selecting investigators who are 
experienced and skilled in their respective areas of surgery, have clinical investigation experience, and 
who are adequately trained on the use of the investigational device and study procedures. 
 
Risks and benefits of this clinical investigation are included in the sample Subject Informed Consent 
Form, included as Appendix B.  Potential risks and benefits will be discussed with potential subjects 
during the informed consent process. 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 47 of 56 
 
14 
REPORTS AND PUBLICATIONS 
 
14.1 Interim Reports 
 
Interim reports will not be issued during the conduct of this clinical investigation.  Thus, if the interim 
analysis support early termination of the clinical investigation, the number of subjects included may be 
higher than the number available at the time of the interim analysis.  All available data for the analysis 
populations defined above will be included in the final analysis and report. 
 
14.2 Final Report 
 
The final report will be compiled by the Sponsor or designated Sponsor representative and reviewed, 
approved and signed off by the co-ordinating investigator. 
 
14.3 Publications 
 
The conduct and results of this clinical investigation will be documented in the final report, as mentioned 
above.  Because this investigation is a multicenter investigation, it is intended that the combined clinical 
data from all participating sites will be presented and/or published.  Individual investigators will not 
publish or present results prior to publication of the combined multicenter results without prior written 
consent from the Sponsor.  All publications must include the name of the Sponsor (Biom’Up, France). 
 
Detailed publication policies will be included within the Investigator Agreement. 
 
15 
ETHICAL CONSIDERATIONS 
 
15.1 Institutional Review Board Approval 
 
Prior to the initiation of this clinical investigation, the Principal Investigator must submit the Clinical 
Investigational Plan, patient consent form and any other documents as may be required to the appropriate 
IRB for review and approval.  The Principal Investigator, and any other member of the investigational 
team, must not participate in the decision-making.  A signed and dated letter granting IRB approval must 
be provided to the Sponsor prior to the initiation of the clinical investigation.  A list of the members of the 
IRB reviewing this Clinical Investigational Plan will be requested. 
 
15.2 Informed Consent and Patient Information 
 
The Principal Investigator or designee must explain to each subject the nature of the clinical investigation, 
including any risks and benefits, its purpose and procedures, and expected duration of involvement in the 
clinical investigation.  Each subject must be informed that participation in the clinical investigation is 
voluntary and non-participation will not affect his/her right to the most appropriate surgical treatment or 
affect the doctor/clinician-patient relationship.  Subjects have the full right to withdraw from the clinical 
investigation at any time, irrespective of their initial consent. 
 
Each subject must also give their permission for representatives of the Sponsor, auditor and regulatory 
authorities to review their hospital records for purposes of source data verification. 
 
15.3 Subject Confidentiality 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 48 of 56 
 
Confidentiality of subject data will be maintained at all times.  Subject anonymity will be guaranteed and 
all documentation relating to a subject will be kept in a secure location. 
 
15.4 Declaration of Helsinki and IDE Regulations 
 
Outside the United States, this clinical investigation will be conducted in accordance with the relevant 
articles of the Declaration of Helsinki as adopted by the 18th World Medical Assembly in 1064 and as 
revised in Tokyo (1975), Venice (1983), Hong Kong (1989), South Africa (1996), Edinburgh (2000), 
Washington (2002), Tokyo (2004) and Seoul (2008).  In the United States, the investigation will be 
conducted in accordance with applicable FDA regulations and guidance, including 21 CFR Parts 50, 56, 
and 812. 
 
15.5 Indemnity 
 
The Sponsor recognizes its liability in law to compensate for any injury sustained by a subject 
participating in this clinical investigation in accordance with applicable laws and guidelines and as agreed 
upon in the Clinical Trial Agreement which each investigational site. 
 
15.6 Insurance 
 
The Sponsor is responsible for obtaining and maintaining clinical investigation insurance. 
 
16 
COMPLIANCE 
 
16.1 Overview 
 
This clinical investigation will be conducted in accordance with Note for Guidance of Good Clinical 
Practice: CPMP/ICH/135/95. 
 
The following Federal Regulations will also be followed: 21 CFR Parts 11, 50, 56, and 812 and 45 CFR 
Part 46. 
 
16.2 Clinical Investigation Personnel Responsibilities 
 
Prior to the initiation of this clinical investigation, each Principal Investigator will approve this Clinical 
Investigational Plan by signing the signature page.  This signature confirms that the clinical investigation 
will be performed in compliance with the Clinical Investigational Plan. 
 
Investigator reporting responsibilities and timelines are included in  
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 49 of 56 
 
Table 11 below.  Applicable IRB procedures and any conditions set forth in the Investigator Agreement 
must also be followed. 
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 50 of 56 
 
Table 11.  Investigator Reporting Responsibilities 
 
Responsibility 
Report To 
Timeline 
Details 
SAEs, SADEs 
Sponsor / 
Sponsor 
Representative 
24 hours 
The Investigator must notify the Sponsor of any 
SAEs, including those that are potentially device-
related, within 24 hours of awareness. 
 
 
 
 
Unanticipated 
[Serious] Adverse 
Device Effects 
(UADEs/USADEs) 
Local IRB/EC 
10 business 
days or less 
and as required 
by local 
IRB/EC policy 
The Investigator must submit evaluation of any 
UADE within 10 business days after Investigator 
awareness and as required by local IRB/EC 
policy. 
Sponsor / 
Sponsor 
Representative 
24 hours 
The Investigator must notify the Sponsor of any 
UADE within 24 hours after Investigator 
awareness. 
Withdrawal of 
IRB/EC approval 
Sponsor / 
Sponsor 
Representative 
5 business 
days 
The Investigator must report a withdrawal of the 
reviewing IRB approval within 5 business days. 
Progress Report 
Sponsor and 
Local IRB/EC 
Yearly 
Progress reports on the investigation will be 
submitted to the Sponsor, monitor, and reviewing 
IRB/EC at regular intervals, but in no event less 
often than yearly, or as required by local IRB/EC 
policy. 
Deviation from 
clinical 
investigational plan 
in emergency 
Sponsor / 
Sponsor 
Representative 
24 hours 
Deviations from the clinical investigational plan 
that are made to protect the life or physical well-
being of a patient in an emergency situation must 
be reported within 24 hours after the emergency 
occurred. 
Local IRB/EC 
5 business 
days or less as 
required by 
applicable 
IRB/EC policy 
Deviations from the clinical investigational plan 
that are made to protect the life or physical well-
being of a patient in an emergency situation must 
be reported within 5 business days after the 
emergency occurred. 
Deviation from 
protocol that affects 
the scientific 
soundness of the 
study plan or the 
rights, safety, or 
welfare of human 
subjects 
Sponsor / 
Sponsor 
Representative 
Prior approval 
Prior approval by the Sponsor is required when a 
deviation of this nature is anticipated. 
Failure to obtain 
informed consent 
Sponsor / 
Sponsor 
Representative 
5 business 
days 
If the investigational device was used without 
obtaining informed consent, the Investigator must 
notify the Sponsor within 5 business days of the 
use of the device. 
Local IRB 
5 business 
days 
If the investigational device was used without 
obtaining informed consent, the Investigator must 
notify the IRB within 5 business days of the use 
of the device. 
Final report 
Sponsor and 
Local IRB/EC 
3 months 
The investigators will submit a final report to the 
Sponsor and local IRB/EC within 3 months after 
termination or completion of the investigation, or 
as required by local IRB/EC policy. 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 51 of 56 
 
 
The Sponsor shall also provide accurate, complete, and current information about any aspect of the 
clinical investigation as requested by FDA or reviewing IRB(s). 
 
The Investigator is also responsible for the retention of the clinical investigation records per 21 CFR Parts 
812.2(b) and 812.140. 
 
The Sponsor reporting responsibilities and timelines are included in  
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 52 of 56 
 
Table 12 below.  
 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 53 of 56 
 
Table 12.  Sponsor Reporting Responsibilities 
Responsibility 
Report To 
Timeline 
Details 
Unanticipated [Serious] 
Adverse Device Effects 
(UADEs/USADEs) 
FDA, all 
reviewing 
IRBs, and 
Investigators 
10 business 
days 
The Sponsor must report the results of an 
evaluation of a UADE to FDA and all 
reviewing IRBs and Investigators within 
10 business days after Sponsor notification. 
Withdrawal of IRB/EC 
approval 
FDA, all 
reviewing 
IRBs, and 
Investigators 
5 business 
days 
The Sponsor must notify FDA and all 
reviewing IRBs and participating 
Investigators of the withdrawal of IRB/EC 
approval of an investigation (or any part of 
an investigation) within 5 business days of 
receipt of the withdrawal of approval, or as 
required by applicable national regulations. 
Current investigator list 
FDA 
6 month 
intervals 
The Sponsor will be a current list of the 
names and addresses of all investigators 
participating in the investigation 6 months 
after FDA approval, and at 6 month 
intervals. 
Progress report 
Reviewing 
IRBs 
Annually 
At regular intervals and at least yearly, the 
Sponsor must provide progress reports to 
all reviewing IRBs. 
Recall and device 
disposition 
FDA and all 
reviewing IRBs 
30 business 
days 
The Sponsor must notify FDA and all 
reviewing IRBs of any request that an 
Investigator return, repair, or dispose of 
any investigational device.  The notice 
must be made within 30 business days after 
the request is made and must state why the 
request was made. 
Final report 
Reviewing 
IRBs, and FDA 
6 months / 12 
months 
The Sponsor will submit a final report to 
FDA and all reviewing IRBs within 6 
months after clinical investigation 
completion or termination.   
Informed consent 
FDA 
5 business 
days 
The Sponsor shall submit to FDA a copy of 
any report by an investigator of use of a 
device without obtaining informed consent 
within 5 business days of receipt of notice 
of such use. 
Significant risk device 
determination 
FDA 
5 business 
days 
If an IRB determines that the device is a 
significant risk device and not a non-
significant risk device as the Sponsor had 
propose to the IRB, a report must be 
submitted to FDA within 5 business days 
after the Sponsor learns of the IRB 
determination. 
 
The Sponsor shall also provide accurate, complete, and current information about any aspect of the 
clinical investigation as requested by FDA or reviewing IRB(s).  Current applicable national regulations 
shall be followed. 
 
The Sponsor is also responsible for the retention of clinical investigation documentation per 21 CFR Parts 
812.2(b) and 812.140 and as required by applicable national regulations. 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 54 of 56 
 
 
16.3 Monitoring 
 
The monitor will be responsible for securing the compliance of the Principal Investigators to the signed 
agreement, the Clinical Investigational Plan, GCP, applicable laws and regulations, and conditions of 
approval imposed by the reviewing IRBs or regulatory authorities. 
 
The Principal Investigator will permit the Sponsor or designated representative of the Sponsor to inspect 
all CRFs and corresponding portions of the subject’s clinic records and/or original hospital medical 
records, at regulatory intervals throughout the clinical investigation.  These inspections are for the 
purpose of verifying adherence to the Clinical Investigational Plan and the completeness and accuracy of 
the data being entered on the CRFs. 
 
The planned extent of source data verification is detailed within the monitoring plan. 
 
A Principal Investigator found not to be in compliance will receive telephone and/or written notification 
of the deficiency, which will include a request that deviation be corrected immediately.  If the corrective 
actions are not taken, shipment of investigational devices to the institution will be suspended.  A request 
will be made to the Principal Investigator that any investigational devices still in his/her possession are 
returned to the Sponsor. 
 
16.4 Audits 
 
During the conduct of the clinical investigation, the Sponsor may appoint Quality Assurance (QA) 
personnel to provide audit of the administration and conduct of the clinical investigation, at the 
investigational site(s), Sponsor, and/or Sponsor representative(s). 
 
The relevant Regulatory Authority also has the right to conduct an audit of the clinical investigation, that 
the clinical investigations were, in fact, performed at stated investigational sites and that the data reported 
to the authority accurately reflects the data in the records of the Principal Investigator.  The authority also 
inspects such studies to verify that the clinical investigations were conducted in accordance with 
applicable laws and regulations.  It is the joint responsibility of the Sponsor and the Principal Investigator 
to ensure that the clinical investigation has been conducted in accordance with all government 
regulations. 
 
In the event that the regulatory authority desires to inspect this clinical investigation, the Principal 
Investigator will permit authorized inspectors to inspect all facilities and records relating to the clinical 
investigation and aid the Inspector to perform the audit in a timely fashion. 
 
16.5 Modifications to the Clinical Investigational Plan 
 
Except in emergency situations, prior approval by the Sponsor is required for changes in or deviations 
from this Clinical Investigational Plan.  This provision does not apply to those changes made to reduce 
discomfort or overt risks to the subject.  In the event of an emergency situation, the Principal Investigator 
must institute any and all medical procedures he/she deems to be medically sound.  All such events and 
procedures must be documented in the subjects Case Report Form and reported within the timelines 
specified in Section 16.2 above. 
 
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 55 of 56 
 
17 
ABBREVIATIONS AND DEFINITIONS 
 
Abbreviation / Term 
Definition 
ACS-ATLS 
American College of Investigators – Advanced Trauma Life 
Support® Shock Risk Class: 1 – involves up to 15% of blood 
volume; typically no charge in vital signs and fluid resuscitation is 
not usually necessary.  Class 2 – involves 15-30% of total blood 
volume; patient is often tachycardic with a narrowing of the 
difference between the systolic and diastolic blood pressures; the 
body attempts to compensate with peripheral vasoconstriction; skin 
may start to look pale and be cool to the touch; volume 
resuscitation with crystalloids is all that is typically required; blood 
transfusion is not typically required.  Class 3 – involved loss of 30-
40% of circulating blood volume; patient’s blood pressure drops; 
heart rate increases, peripheral hypoperfusion worsens; fluid 
resuscitation with crystalloid and blood transfusion are usually 
necessary.  Class 4 – involves loss of > 40% of circulating blood 
volume; the limit of the body’s compensation is reached and 
aggressive resuscitation is required to prevent death. 
ADE 
Adverse Device Effect - any untoward and unintended response to 
an investigational medical device 
AE 
Adverse Event - any untoward medical occurrence in a subject 
Antiplatelet Medications 
• 
Abciximab  
• 
Anagrelide 
• 
Dipyridamole  
• 
Cilostazol  
• 
Clopidogrel  
• 
Eptifibatide  
• 
Prasugrel  
• 
Terutoban 
• 
Ticagrelor  
• 
Ticlopidine  
• 
Tirofiban  
• 
Vorapaxar  
ASA Classification 
American Society of Anesthesiologists Classification: 1 – normal 
health patient; 2 – patient with mild systemic disease; 3 – patient 
with severe systemic disease; 4 – patient with severe systemic 
disease that is constant threat to life; 5 – moribund patient who is 
not expected to survive with the operation; 6 – a declared brain-
dead patient whose organs are being removed for donor purposes 
CEC 
Clinical Events Committee 
CFR 
Code of Federal Regulations 
CRF 
Case Report Form 
Device deficiency 
Inadequacy of a medical device with respect to its identity, quality, 
durability, reliability, safety or performance, which may include 
device malfunctions, use errors and inadequate labelling 
Enrollment 
For this investigation, the point of enrollment is intraoperatively, 
when the subject meets all intraoperative inclusion criteria 
FDA 
Food and Drug Administration  

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 56 of 56 
 
ICF 
Informed Consent Form 
IDMC 
Independent Data Monitoring Committee 
INR 
International Normalized Ratio 
Intraoperative Time 
Time from skin open to skin closure 
IRB 
Institutional Review Board 
QA 
Quality Assurance 
Relationship (of an 
adverse event to the 
investigational device) 
• 
Not related: the adverse event is due to the underlying 
disease state or is due to concomitant medications or 
therapy not related to the use of the device 
• 
Possibly related: the adverse event has a reasonable 
temporal relationship to the use of the device but 
alternative etiology is equally or more likely compared to 
the potential relationship to the use of the device 
• 
Probably related: the adverse event has a strong temporal 
relationship to the use of the device and alternative etiology 
is less likely compared to the potential relationship to the 
use of the device 
• 
Definitely related: the adverse event has a strong temporal 
relationship to the use of the device, follows a known 
response pattern and cannot reasonably be explained by 
known characteristics of the subject’s clinical state or other 
therapies 
SADE 
Serious Adverse Device Effect – an adverse device effect that has 
resulted in any of the consequences characteristic of a serious 
adverse event or that might have led to any of these consequences if 
suitable action had not been taken or intervention had not been 
made or if circumstances had been less opportune 
SAE 
Serious Adverse Event – an adverse event that: 
• 
Led to death 
• 
Led to a serious deterioration in the health of the subject, 
that either resulted in a life-threatening illness or injury, or 
a permanent impairment of a body structure or a body 
function, or in-patient hospitalization or prolongation of 
existing hospitalization, or resulted in medical or surgical 
intervention to prevent life-threatening illness or injury or 
permanent impairment to a body structure or a body 
function 
• 
 
SBSS 
Surface Bleeding Severity Scale 
Severity (of an adverse 
event) 
• 
Mild: the symptoms are transient, barely perceptible by the 
subject and do not hinder normal activity; no treatment is 
usually prescribed to reduce these symptoms 
• 
Moderate: the symptoms are sufficiently severe to provoke 
discomfort in the subject and sufficiently uncomfortable to 
prevent normal activity; a treatment may be required 
• 
Severe: the symptoms considerably modify the normal 
course of the subject’s activities or are disabling or are life-
threatening; the treatment studied should be suspended; a 
treatment for the symptoms is prescribed 
Significant coagulation 
For this investigation, a significant coagulation disorder is a platelet 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 57 of 57 
 
disorder 
count < 100,000 per microliter or International Normalized Ratio > 
1.5 
TBS 
Target Bleeding Site 
TTH 
Time to hemostasis 
UADE (also USADE) 
Unanticipated [Serious] Adverse Device Effect – any serious 
adverse effect on health or safety, any life-threatening problem or 
death caused by, or associated with a device, if that effect, problem, 
or death was not previously identified in nature, severity, or degree 
of incidence in the application; or any other unanticipated serious 
problem associated with a device that relates to the rights, safety or 
welfare of subjects 
WHO 
World Health Organization 
 
18 
REFERENCES 
 
                                                            
1 Oz MC, et al.  Controlled clinical trial of a novel hemostatic agent in cardiac surgery.  The Fusion Matrix Study 
Group.  Ann Thorac Surg 2000;69(5):1376-1382. 
2 Doria C, et al.  Phase 3, randomized, double-blind study of plasma-derived human thrombin versus bovine 
thrombin in achieving hemostasis in patients undergoing surgery.  Curr Med Res Opin 2008;24(3):785-794. 
3 Jackson MR, et al. Hemostatic efficacy of fibrin sealant (human) on expanded polytetrafluoroethylene carotid 
patch angioplasty: a randomized clinical trial.  J Vasc Surg 1999;30(3):461-467. 
4 Nasso G, et al.  Prospective, randomized clinical trial of the Floseal matrix sealant in cardiac surgery.  Ann Thorac 
Surg 2009;88:1520-1526. 
5 Weaver FA, et al.  Gelatin-thrombin-based hemostatic sealant for intraoperative bleeding in vascular surgery.  Ann 
Vasc Surg 2002;16:286-293. 
6 Boucher BA, et al.  Achieving hemostasis in the surgical field.  Pharamacotherapy 2009;29:2S-7S. 
7 Levy JH, et al.  Multidisciplinary approach to the challenge of hemostasis.  Anesth Analg 2010;110:354-364. 
8 Adams GL, et al.  The balance of thrombosis and hemorrhage in surgery.  Hematol Oncol Clin North AM 
2007;21(1):13-24. 
9 Renkens KL, et al.  A multicenter, prospective, randomized trial evaluating a new hemostatic agent for spinal 
surgery.  Spine 2001;26(15):1645-1650. 
10 Tomizawa Y, et al.   Clinical benefits and risk analysis of topical hemostats: a review.  J Artif Organs 
2005;8(3):137-142. 
11 Samudrala S.  Topical hemostatic agents in surgery: a surgeon’s perspective.  AORN J 2008;99(3):S2-S11. 
12 Oz MC, et al.  Floseal® Matrix: new generation topical hemostatic sealant.  J Card Surg 2003;18:486-493. 
13 Mangano DT, et al.  Mortality associated with aprotinin during 5 years following coronary artery bypass graft 
surgery.  JAMA 2007;297(5):471-479. 
14 Fergusson DA, et al.  A comparison of aprotinin and lysine analogues in high-risk cardiac surgery.  N Eng J Med 
2008;358:2319-2331. 
15 Mangano DT, Tudor IC, Dietzel C, for the Multicenter Study of Perioperative Ischemia (McSPI) Research Group 
and the Ischemia Research and Education Foundation.  The risk associated with aprotinin in cardiac surgery.  N Engl 
J Med 2006;354-365. 
16 Achneck HE, et al.  A comprehensive review of topical hemostatic agents: efficacy and recommendations for use.  
Ann Surg 2010;25(2):217-228. 
17 Spotnitz WD.  Hemostats, sealants, and adhesives: components of the surgical toolbox.  Transfusion 2008;1502-
1516. 
18 Ge M, Durham LK, Meyer RD, Xie W and Thomas N. Covariate-Adjusted Difference in Proportions from 
Clinical Trials Using Logistic Regression and Weighted Risk Differences. Drug Information Journal. 2011; 45: 481 
- 493  
 

 
 
Clinical Investigational Plan ETC 2015-002 
 
 
Version 4.0 
Confidential 
 
Page 58 of 58 
 
                                                                                                                                                                                               
19 Jennison C and Turnbull B. Interim Analyses: The Repeated Confidence Interval Approach. Journal of the Royal 
Statistical Society. Series B (Methodological) Vol. 51, No. 3 (1989), pp. 305-361. 
20 Kittelson JM and Emerson SS.  (1990).  A unifying family of group sequential test designs.  Biometrics 55, 874-
923. 
21 Pocock SJ.  (1977).  Group sequential methods in the design and analysis of clinical trials.  Biometrika 64, 191-
199. 
22 O’Brien PC and Fleming TR.  (1979).  A multiple testing procedure for clinical trials.  Biometrics 35, 549-556. 
23 Burington BE and Emerson SS.  (2003).  Flexible implementations of group sequential stopping rules using 
constrained boundaries.  Biometrics 59, 770-777.